Antithrombotic Compounds, Methods and Uses Thereof

ABSTRACT

Provided herein are polymers and methods for their use in binding a phosphate containing biological macromolecules. Specifically, the methods and uses provided herein may be used to inhibit thrombin binding to polyphosphate or as an antithrombotic agent for the treatment of stroke, acute coronary syndrome, pulmonary embolism, atrial fibrillation, venous and arterial thromboembolism, disseminated intravascular coagulation (DIC), deep-vein thrombosis (DVT), peripheral artery disease, trauma-induced coagulopathy, extracorporeal circulation, cancer-associated thrombosis, sepsis, septic shock, Systemic Inflammatory Response Syndrome (SIRS), or inflammation.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional PatentApplication Ser. No. 62/004,866 filed on 29 May 2014 entitled“ANTITHROMBOTIC COMPOUNDS”.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with government support under contract numbersR01 HL047014, awarded by the National Institutes of Health, and AHAPredoctoral Fellowship 13PRE14550007, awarded by the American HeartAssociation. The government has certain rights in the invention.

TECHNICAL FIELD

This invention relates to therapeutics, their uses and methods for theinhibition of thrombosis. In particular the invention relates totherapies and methods of treatment for stroke, heart attack, orpulmonary embolism.

BACKGROUND

Polyphosphate (polyP) is a highly anionic, linear polymer of inorganicphosphate that accumulates in many infectious microorganisms (1) and issecreted by activated human platelets (2). The platelet polyP acts as aprocoagulant stimulus at a number of points in the coagulation cascadeincluding: accelerating factor V activation, antagonizing theanticoagulant function of tissue factor pathway inhibitor (TFPI), makingclots more resistant to fibrinolysis, and enhancing factor XI activationby thrombin (3). Although, current understanding of the mechanismsbehind polyP's acceleration of clotting and which mechanisms are mostrelevant in vivo, are incomplete. The role of platelet polyP inhemostasis and thrombosis suggests that it may contribute more heavilyto thrombosis. Additionally, its role as an accelerant rather than a keyenzyme in the final common pathway of the coagulation cascade (unlike,for example, thrombin or factor Xa), suggests that platelet polyP is anattractive therapeutic target for novel antithrombotics with potentiallydecreased bleeding risk compared to conventional therapies (4). Currentantithrombotic drugs used in a clinical setting include, heparin, whichhas significant toxicity in cell culture (5) and carries risk of majorbleeding events and heparin-induced thrombocytopenia, even inheparin-naive patients (6, 7).

Cationic polymers make attractive candidates for high-affinity polyPinhibitors, and such polymers, including polyethylenimine (PEI) andpolyamidoamine (PAMAM) dendrimers, have proven effective in attenuatingthrombosis in proof-of-principle studies that identified polyP as atherapeutic target (8, 9). Both of these types of polymers arepositively charged due the presence of multiple primary amines, whichallows them to bind to and inhibit polyP, but this property can alsopromote binding to proteins and cell surfaces and thus lead to cellulartoxicity, platelet activation, and coagulopathy mediated by fibrinogenaggregation (10, 11). This severely limits the real-world usefulness ofthese previously identified polyP inhibitors.

SUMMARY

The present invention is based, in part, on the surprising discoverythat some polymers that are Universal Heparin Reversal Agents (UHRAs)having low molecular weight and higher charge density as describedherein are useful as polyphosphate (polyP) inhibitors and thus may beuseful as antithrombotic agents (i.e. as inhibitors of PolyP binding tothrombin). As described herein particular UHRAs are unique since theselectivity of the molecules towards polyP is different in comparison toheparin, especially in vivo. As described herein, numerous UHRA polymersstrongly inhibited the polyP pro-coagulant activity in vitro. Four ofthose UHRAs were selected for further in vivo testing in mouse models ofthrombosis and hemostasis. Furthermore, these UHRA polymers were foundto have significantly less bleeding as compared with therapeuticallyequivalent antithrombotic doses of heparin in mouse tail bleedingassays. Accordingly, the polymers described herein may providealternative antithrombotic agents that target procoagulant anionicpolymers (for example polyP), but that have reduced toxicity andbleeding as compared to known anti-thrombotic agents. Furthermore, thepolymers described herein have also been shown to bind other anionicpolymers, like extracellular nucleic acids, which have also beenimplicated in thrombosis. The polymers described herein may be used asantithrombotic agents. Furthermore, the polymers described herein may beused in the treatment of any one or more of stroke, acute coronarysyndrome, pulmonary embolism, atrial fibrillation, venous or arterialthromboembolism, disseminated intravascular coagulation (DIC), deep-veinthrombosis (DVT), peripheral artery disease, trauma-inducedcoagulopathy, extracorporeal circulation, cancer-associated thrombosis,sepsis, septic shock, Systemic Inflammatory Response Syndrome (SIRS) andinflammation.

Herein are presented compositions and methods for their use in treatmentof stroke, acute coronary syndrome (for example, myocardial infarction(MI) or acute myocardial infarction (AMI)), pulmonary embolism, atrialfibrillation, venous or arterial thromboembolism, disseminatedintravascular coagulation (DIC), sepsis, septic shock, SIRS, deep-veinthrombosis (DVT), peripheral artery disease, trauma-inducedcoagulopathy, extracorporeal circulation, cancer-associated thrombosisand inflammation. Furthermore, the polymers described herein may be usedto replace heparin treatment, wherein the subject would also benefitfrom reduced blood loss (i.e. acute coronary syndrome (i.e. MI or AMI(usually due to non-ST elevation myocardial infarction (NSTEMI), STelevation myocardial infarction (STEMI) or unstable angina), atrialfibrillation, deep-vein thrombosis (DVT), and pulmonary embolism).

In one aspect, there is provided a method of binding a phosphatecontaining biological macromolecule, the method includes adding apolymer to a phosphate containing biological macromolecule sample,wherein the polymer comprises: a) a dendritic polyglycerol core having2-33 randomly distributed tetra-amine groups, wherein the tetra-amineshave the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system.

In another aspect of the invention, there is provided a method ofbinding a phosphate containing biological macromolecule, the methodincluding administering a polymer to a subject in need of havingphosphate containing biological macromolecules bound, wherein thepolymer comprises: a) a dendritic polyglycerol core having 5-33 randomlydistributed tetra-amine groups, wherein the tetra-amines have thefollowing structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5 and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system.

In another aspect of the invention, there is provided a use of a polymerto bind a phosphate containing biological macromolecule, wherein thepolymer includes: a) a dendritic polyglycerol core having 2-33 randomlydistributed tetra-amine groups, wherein the tetra-amines have thefollowing structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system.

In another aspect of the invention, there is provided a use of a polymerthe polymer includes: a) a dendritic polyglycerol core having 2-33randomly distributed tetra-amine groups, wherein the tetra-amines havethe following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system, for the treatment of one ormore of: stroke; acute coronary syndrome; pulmonary embolism; atrialfibrillation; venous or arterial thromboembolism; disseminatedintravascular coagulation (DIC); deep-vein thrombosis (DVT); peripheralartery disease; trauma-induced coagulopathy; extracorporeal circulation;cancer-associated thrombosis; sepsis; septic shock; SystemicInflammatory Response Syndrome (SIRS); and inflammation.

In another aspect of the invention, there is provided a use of apolymer, wherein the polymer includes: a) a dendritic polyglycerol corehaving 5-33 randomly distributed tetra-amine groups, wherein thetetra-amines have the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5 and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system, in the manufacture of amedicament for inhibiting thrombin binding to polyphosphate in asubject.

In another aspect of the invention, there is provided a use of apolymer, wherein the polymer includes: a) a dendritic polyglycerol corehaving 5-33 randomly distributed tetra-amine groups, wherein thetetra-amines have the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5 and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system, in the manufacture of amedicament for treating one or more of: stroke; acute coronary syndrome;pulmonary embolism; atrial fibrillation; venous or arterialthromboembolism; disseminated intravascular coagulation (DIC); deep-veinthrombosis (DVT); peripheral artery disease; trauma-inducedcoagulopathy; extracorporeal circulation; cancer-associated thrombosis;sepsis; septic shock; Systemic Inflammatory Response Syndrome (SIRS);and inflammation in a subject.

In another aspect of the invention, there is provided a polymer forinhibiting thrombin binding to polyphosphate in a subject, wherein thepolymer includes: a) a dendritic polyglycerol core having 2-33 randomlydistributed tetra-amine groups, wherein the tetra-amines have thefollowing structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system.

In another aspect of the invention, there is provided a polymer for thetreatment of one or more of: stroke; acute coronary syndrome; pulmonaryembolism; atrial fibrillation; venous or arterial thromboembolism;disseminated intravascular coagulation (DIC); deep-vein thrombosis(DVT); peripheral artery disease; trauma-induced coagulopathy;extracorporeal circulation; cancer-associated thrombosis; sepsis; septicshock; Systemic Inflammatory Response Syndrome (SIRS); and inflammationin a subject, wherein the polymer includes: a) a dendritic polyglycerolcore having 2-33 randomly distributed tetra-amine groups, wherein thetetra-amines have the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system.

In another aspect of the invention, there is provided a polymer polymerfor use as an antithrombotic agent, wherein the polymer includes: a) adendritic polyglycerol core having 2-33 randomly distributed tetra-aminegroups, wherein the tetra-amines have the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system.

In another aspect of the invention, there is provided a commercialpackage including a polymer, wherein the polymer includes: a) adendritic polyglycerol core having 2-33 randomly distributed tetra-aminegroups, wherein the tetra-amines have the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed ₄.₅; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system, and instructions for use in thetreatment of stroke; acute coronary syndrome; pulmonary embolism; atrialfibrillation; venous or arterial thromboembolism; disseminatedintravascular coagulation (DIC); deep-vein thrombosis (DVT); peripheralartery disease; trauma-induced coagulopathy; extracorporeal circulation;cancer-associated thrombosis; sepsis; septic shock; SystemicInflammatory Response Syndrome (SIRS); and inflammation.

In another aspect of the invention, there is provided a commercialpackage including a polymer wherein the polymer includes: a) a dendriticpolyglycerol core having 2-33 randomly distributed tetra-amine groups,wherein the tetra-amines have the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system, and instructions for use ininhibiting thrombin binding to polyphosphate.

In another aspect of the invention, there is provided a commercialpackage including a polymer wherein the polymer includes: a) a dendriticpolyglycerol core having 2-33 randomly distributed tetra-amine groups,wherein the tetra-amines have the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4-5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system, and instructions for use as anantithrombotic agent.

The outer shell may be a hydrophilic polymeric system. Such an outershell may be a pharmaceutically acceptable and biocompatible, especiallywhere a polymer is for administration to a subject or for thepurification of or extraction from a biological fluid (for example,blood). The hydrophilic polymeric system may be a polyether orpolyalcohol. The polyether or polyalcohol may be a low molecular weightpolyglycerol, linear polyglycerol, oligosaccharides,poly(N-isopropylacrylamide(PNIPAM), polyacrylamide (PAM),poly(2-oxazoline), poly(ethylene glycol), methoxy (polyethylene glycol),poly(ethylene oxide), poly(vinyl alcohol) (PVA), orpoly(vinylpyrrolidone) (PVP) or other water soluble polymers or acombination thereof. The hydrophilic polymeric system may be PEG, PEG-OHor PEG-OMe or a combination thereof. The hydrophilic polymeric systemmay be

or a combination thereof, wherein n is 0-100, x is 0-100 and y is 0-100.The outer shell may be selected from one or more of:

wherein n is 0-100, x is 0-100 and y is 0-100. The outer shell polymerdensity of a compound may be given as a wt %. The compounds may have PEGby weight in the range 60-75 wt %. The compounds may have PEG by weightin the range 10 to 90 wt %.

n may be an integer between 1 and 100, m may be an integer between 1 and100 and y may be an integer between 1 and 100. n may be an integerbetween 1 and 90, m may be an integer between 1 and 90 and y may be aninteger between 1 and 90. n may be an integer between 1 and 80, m may bean integer between 1 and 80 and y may be an integer between 1 and 80. nmay be an integer between 1 and 70, m may be an integer between 1 and 70and y may be an integer between 1 and 70. n may be an integer between 1and 60, m may be an integer between 1 and 60 and y may be an integerbetween 1 and 60. n may be an integer between 1 and 50, m may be aninteger between 1 and 50 and y may be an integer between 1 and 50. n maybe an integer between 1 and 40, m may be an integer between 1 and 40 andy may be an integer between 1 and 40. n may be an integer between 1 and30, m may be an integer between 1 and 30 and y may be an integer between1 and 30. n may be an integer between 1 and 25, m may be an integerbetween 1 and 25 and y may be an integer between 1 and 25. n may be aninteger between 1 and 20, m may be an integer between 1 and 20 and y maybe an integer between 1 and 20. n may be an integer between 1 and 10, mmay be an integer between 1 and 10 and y may be an integer between 1 and10. n may be an integer between 1 and 9, m may be an integer between 1and 9 and y may be an integer between 1 and 9. n may be an integerbetween 1 and 8, m may be an integer between 1 and 8 and y may be aninteger between 1 and 8. n may be an integer between 1 and 7, m may bean integer between 1 and 7 and y may be an integer between 1 and 7. nmay be an integer between 1 and 6, m may be an integer between 1 and 6and y may be an integer between 1 and 6. n may be an integer between 1and 5, m may be an integer between 1 and 5 and y may be an integerbetween 1 and 5. n may be an integer between 3 and 10, m may be aninteger between 3 and 10 and y may be an integer between 3 and 10. n maybe an integer between 4 and 9, m may be an integer between 4 and 9 and ymay be an integer between 4 and 9. n may be an integer between 5 and 8,m may be an integer between 5 and 8 and y may be an integer between 5and 8.

The binding of the phosphate containing biological macromolecule mayresult in neutralization. The phosphate containing biologicalmacromolecule may be polyphosphate or a nucleic acid. The phosphatecontaining biological macromolecule may be polyphosphate. The binding topolyphosphate may disrupt the interaction between thrombin andpolyphosphate.

The polyglycerol core may have between 4-50 randomly distributedtetra-amine groups. The polyglycerol core may have between 5-33 randomlydistributed tetra-amine groups. The polyglycerol core may have between7-24 randomly distributed tetra-amine groups. The polyglycerol core mayhave between 11-24 randomly distributed tetra-amine groups. Thepolyglycerol core may have between 12-23 randomly distributedtetra-amine groups. The polyglycerol core may have between 7-16 randomlydistributed tetra-amine groups. The polyglycerol core may have between8-16 randomly distributed tetra-amine groups.

The molecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 4.5. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.5 and 4.5. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.1 and 4.5. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 4.0. The molecular weight of the polymer in kDa pertetra-amine group may be between o.8 and 4.0. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.9 and 3.9. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 3.8. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 3.7. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.9 and 3.6. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 3.5. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 3.4. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.9 and 3.3. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 3.2. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 3.1. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.9 and 3.0. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 2.9. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 2.8. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.9 and 2.7. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 2.6. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 2.5. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.7 and 2.5. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.8 and 2.5. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 2.4. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.9 and 2.3. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 2.2. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 2.1. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.9 and 2.0. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 1.9. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 1.8. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.9 and 1.7. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.9 and 1.6. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 1.5. The molecular weight ofthe polymer in kDa per tetra-amine group may be between 0.8 and 1.5. Themolecular weight of the polymer in kDa per tetra-amine group may bebetween 0.7 and 1.5. The molecular weight of the polymer in kDa pertetra-amine group may be between 0.9 and 1.4. Alternatively, themolecular weight of the polymer in kDa per tetra-amine may not exceed3.6.

The polymer may have an IC₅₀ (nM) for inhibition of thrombin binding topolyphosphate that is equal to or less than 50 nM. The polymer may havean IC₅₀ (nM) for inhibition of thrombin binding to polyphosphate that isequal to or less than 45 nM. The polymer may have an IC₅₀ (nM) forinhibition of thrombin binding to polyphosphate that is equal to or lessthan 40 nM. The polymer may have an IC₅₀ (nM) for inhibition of thrombinbinding to polyphosphate that is equal to or less than 35 nM. Thepolymer may have an IC₅₀ (nM) for inhibition of thrombin binding topolyphosphate that is equal to or less than 30 nM. The polymer may havean IC₅₀ (nM) for inhibition of thrombin binding to polyphosphate that isequal to or less than 25 nM. The polymer may have an IC₅₀ (nM) forinhibition of thrombin binding to polyphosphate that is equal to or lessthan 20 nM. The polymer may have an IC₅₀ (nM) for inhibition of thrombinbinding to polyphosphate that is equal to or less than 15 nM. Thepolymer may have an IC₅₀ (nM) for inhibition of thrombin binding topolyphosphate that is equal to or less than 10.2 nM. The polymer mayhave an IC₅₀ (nM) for inhibition of thrombin binding to polyphosphatethat is equal to or less than 10 nM.

The polyglycerol core may have a degree of branching in the range ofabout 0.05 to about 0.95. The polyglycerol core may have a degree ofbranching in the range of about 0.10 to about 0.95. The polyglycerolcore may have a degree of branching in the range of about 0.10 to about0.90. The polyglycerol core may have a degree of branching in the rangeof about 0.15 to about 0.85. The polyglycerol core may have a degree ofbranching in the range of about 0.25 to about 0.75. The polyglycerolcore may have a degree of branching in the range of about 0.35 to about0.65. The polyglycerol core may have a degree of branching in the rangeof about 0.40 to about 0.60. The polyglycerol core may have a degree ofbranching in the range of about 0.40 to about 0.65.

The polymer may be UHRA-1, UHRA-2, UHRA-5, UHRA-6, UHRA-7, UHRA-8,UHRA-9, UHRA-10, UHRA-11, UHRA-13, UHRA-14 or UHRA-15. The polymer maybe UHRA-2, UHRA-5, UHRA-6, UHRA-7, UHRA-8, UHRA-9, UHRA-10, UHRA-11,UHRA-13, UHRA-14 or UHRA-15. The polymer may be UHRA-2, UHRA-5, UHRA-6,UHRA-7, UHRA-8, UHRA-9, UHRA-10, UHRA-11, UHRA-13 or UHRA-14. Thepolymer may be UHRA-5, UHRA-6, UHRA-7, UHRA-8, UHRA-9, UHRA-10, UHRA-11,UHRA-13 or UHRA-14. The polymer may be UHRA-6, UHRA-7, UHRA-8, UHRA-9,UHRA-10, UHRA-11 or UHRA-14. The polymer may be UHRA-6, UHRA-7, UHRA-8,UHRA-9, UHRA-10 or UHRA-11. The polymer may be UHRA-7, UHRA-8, UHRA-9,UHRA-10 or UHRA-11. The polymer may be UHRA-5, UHRA-2, UHRA-7 orUHRA-11. The polymer may be UHRA-8, UHRA-9, UHRA-10 or UHRA-14. Thepolymer may be UHRA-8, UHRA-9 or UHRA-10. The polymer may be UHRA-8 orUHRA-10. The polymer may be UHRA-9 or UHRA-10. The polymer may beUHRA-10.

The subject may be administered the polymer to treat stroke, acutecoronary syndrome, pulmonary embolism, atrial fibrillation, venous andarterial thromboembolism, disseminated intravascular coagulation (DIC),deep-vein thrombosis (DVT), peripheral artery disease, trauma-inducedcoagulopathy, extracorporeal circulation, cancer-associated thrombosis,sepsis, septic shock, Systemic Inflammatory Response Syndrome (SIRS), orinflammation. The subject may be administered the polymer to treatstroke, acute coronary syndrome, pulmonary embolism, atrialfibrillation, venous and arterial thromboembolism, disseminatedintravascular coagulation (DIC), deep-vein thrombosis (DVT), peripheralartery disease, trauma-induced coagulopathy, extracorporeal circulationor cancer-associated thrombosis. The subject may be administered thepolymer to treat stroke, acute coronary syndrome, pulmonary embolism,atrial fibrillation, venous and arterial thromboembolism, disseminatedintravascular coagulation (DIC), deep-vein thrombosis (DVT) orperipheral artery disease. The subject may be administered the polymerto treat stroke, acute coronary syndrome, pulmonary embolism, atrialfibrillation, venous and arterial thromboembolism, disseminatedintravascular coagulation (DIC) or deep-vein thrombosis (DVT). Thesubject may be administered the polymer to treat stroke, acute coronarysyndrome, pulmonary embolism, atrial fibrillation or venous/arterialthromboembolism. The subject may be administered the polymer to treatstroke, acute coronary syndrome, pulmonary embolism, atrial fibrillationor thromboembolism. The subject may be administered the polymer to treatstroke, acute coronary syndrome or pulmonary embolism, atrialfibrillation or venous/arterial thromboembolism.

The polymer may be immobilized on a support. The polymer may beadministered in a dose range of 1 mg/kg to 1000 mg/kg. The polymer maybe administered in a dose range of 50-100 mg/kg. The subject may benon-human. The subject may be human. The subject may be a non-humanmammal. The subject may be a mouse, a rat, a pig, a dog, a cat, a horse,a sheep, a cattle, a goat or a chicken. The shell polymer may be betweenabout 10 to about 90 wt %.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows a representative structure of a UHRA scaffold (i.e.UHRA-10), containing a dendritic polyglycerol core bearing the randomlydistributed polyP-binding groups (R) and an outer shell of short-chainpolyethylene glycols (the molecular weight and number of R groups wasvaried to generate the other UHRAs). However, it will be appreciated bya person of skill in the art, that the structure shown is not a uniquelydefined structure. Based on the way the polymers are synthesized thereis some variation in the structure possible.

FIG. 1B shows the binding group (R group) in two formats (I)un-protonated and (II) protonated structure at physiological pH (pH 7.4)when the tertiary amine groups are protonated to provide the cationicbinding moiety.

FIG. 2 shows biocompatibility of UHRAs compared to other polyPinhibitors: (A) graphs the ability of UHRA compounds, protamine sulfate(PS) and PEI (tested at 1 or 2 mg/mL) to activate complement in humanserum as a measurement of sheep erythrocyte complement consumption,wherein the heat-aggregated human IgG (1 mg/mL) and PBS were thepositive and negative controls, respectively. The UHRAs did not activatecomplement compared to buffer controls, while protamine and PEI showedhigh levels of complement activation in the assay; and (B) graphs theability of UHRA compounds, protamine and PEI (tested at 1 and 2 mg/mL)to activate platelets in human platelet-rich plasma (PRP) as measured byflow cytometry for expression of platelet activation marker CD62P, wherebovine thrombin (at 1 IU/mL) was used as the positive control, and PBSalone was the negative control (“buffer control”). The UHRAs showed lowlevels of platelet activation compared to PEI.

FIG. 3 shows UHRA compounds inhibit thrombus formation in mousecremaster arterioles, with (A-E) showing binarized images from onerepresentative injury each showing the accumulation of platelets andfibrin (arrows) at various time intervals up to 120 seconds afterlaser-induced injury to the vessel wall in mice administered either (A)saline or the following UHRA compounds at 40 μg/g: (B) UHRA 8, (C) UHRA9, (D) UHRA 10, or (E) UHRA 14 (Scale bars: 10 μm) and (F-I) show thestatistical analyses of the effect of administering UHRA compound onthrombus formation. The data was collected from 27-30 injuries to 5 micefor each group, with the median integrated fluorescence intensities(non-binarized) plotted versus time for accumulation of (F) forplatelets and (H) for fibrin, and the area under the curve (totalfluorescence intensity) was plotted for accumulation of (G) in plateletsand (I) in fibrin (each point representing one injury), and the medianvalues were evaluated by Mann-Whitney test, both UHRA 9 and 10significantly reduced total accumulation of platelets and fibrincompared to control. *P<0.05, ***P<0.0005.

FIG. 4 shows UHRA 10 inhibits thrombus formation in mouse cremasterarterioles in a dose-dependent manner in (A-E) which shows binarizedimages from one representative injury each showing the effects onaccumulation of platelets and fibrin (arrows) at various time intervalsup to 120 seconds after laser-induced injury to the vessel wall in miceadministered either (A) saline or UHRA 10 at (B) 10 μg/g, (C) 20 μg/g,(D) 40 μg/g, or (E) 80 μg/g (Scale bars: 10 μm) and (F-I) show thestatistical analyses of the dose-dependent attenuation of thrombusformation by UHRA 10; data were collected from 27-30 injuries to 5 micefor each group, with the median integrated fluorescence intensities(non-binarized) plotted versus time for accumulation of (F) plateletsand (H) fibrin and the area under the curve (total fluorescentintensity) for each individual injury was plotted for accumulation of(G) platelets and (I) fibrin (each point represents one injury). (Note:data for saline control and UHRA at 40 μg/g are in common with the datafrom FIG. 3 and are therefore repeated here in panels A and D, and theblue lines and data points in panels F-I.) with median values beingcompared to saline control for statistical significance by Mann-Whitneytest, where UHRA 10 significantly reduced platelet accumulation at dosesof 20 and 40 μg/g, and significantly reduced fibrin accumulation atdoses of 40 and 80 μg/g. *P<0.05, **P<0.005, ***P<0.0005.

FIG. 5 shows UHRA 10 delays time to occlusion in a mouse carotid arterymodel of thrombosis, where artery patency was monitored by Doppler flowprobe following induction of FeCl₃-mediated injury, and plotted versustime, where the saline control (solid black), unfractionated heparin(grey 1000 and 200 U/kg) and for UHRA 10 (dashed black 100 and 200mg/kg), where both heparin and UHRA 10 significantly delayed median timeto occlusion in a dose-dependent manner (P<0.0001) and Heparin at 200U/kg was not significantly more effective than UHRA 10 at 100 μg/g atmaintaining artery patency (P=0.85), while both treatment conditionssignificantly increased median patency time versus saline control(P=0.0004 for UHRA 10 and P=0.007 for heparin), the UHRA 10 at 200 μg/gor heparin at 1000 U/kg resulted in 100% patency over the 30 minuteperiod for all mice (n=7 for all conditions)—statistical significancewas assessed by log-rank analysis.

FIG. 6 shows antithrombotic doses of UHRA 10 caused less bleeding thandid heparin in a mouse tail bleeding model: with (A) showing bleedingtimes in mice treated with 200 U/kg unfractionated heparin havingsignificantly longer tail bleeding times than did either saline controlmice or mice treated with 50 or 100 μg/g UHRA 10 and similarly, micetreated with 1000 U/kg heparin had significantly longer bleeding timesthan did mice treated with 200 μg/g UHRA 10; and (B) showing blood loss(quantified as mg hemoglobin collected during 30 min) in mice treatedwith either 200 or 1000 U/kg heparin had significantly higher hemoglobinloss than did mice treated with saline and mice treated with 1000 U/kgheparin had significantly more hemoglobin loss than did mice treatedwith 50 or 100 μg/g UHRA 10, while mice treated with 1000 U/kg heparinhad no significant difference in hemoglobin loss compared to micetreated with 200 μg/g UHRA 10—Statistical significance was assessed byindividual Student's t-tests; *P<0.05, **P<0.005, ***P<0.0005.

FIG. 7 shows doses of UHRA 8, 9, 10, and 14 up to 1.5 mg/mL havingslight increases in tissue factor-initiated plasma clotting, whereinplasma clotting times were quantified at ₃₇° C. using a STart4coagulometer (Diagnostica Stago™) and all clotting assays used finalconcentrations of 33% pooled normal human plasma (George KingBio-Medical™), 25 μM liposomes (70:30 ratio of phosphatidylcholine tophosphatidylserine), 41.7 mM imidazole pH 7.0 and 8.33 mM CaCl₂, and aconcentration of relipidated human tissue factor was chosen to givebaseline clot times of approximately 35 seconds, with varyingconcentrations of each of the UHRA compound were mixed with pre-warmedtissue factor and plasma, followed by the addition of pre-warmed calciumchloride solution to induce clotting.

FIG. 8 shows isothermal titration calorimetry analysis for UHRA-polyPbinding. (A-D) Raw data and integral heats for the titration ofdifferent UHRAs (A UHRA-8; B UHRA-9; C UHRA-10; D UHRA-14) into polyP₇₅in 10 mM phosphate buffered saline (PBS) at pH 7.4 and 25° C., wherein aone-site binding model was used to obtain fit for all the titrationdata. Thermodynamic parameter analysis is presented in TABLE 3.

FIG. 9 shows PAMAM dendrimers, but not UHRA compounds induce fibrinogenaggregation, wherein turbidity assays were adapted from previous reportsof dendrimer-induced fibrinogen aggregation (30), and the PAMAMdendrimer generations 1-7, or UHRA compounds 8, 9, 10 or 14, werediluted in TBSC (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 2.5 mM CaCl₂, 0.02%NaN₃) and added to wells of a 96-well plate, where an equal volume of 4mg/mL human fibrinogen (Enzyme Research Laboratories™) diluted in TBSCwas added (final fibrinogen concentration of 2 mg/mL) immediately beforerecording the absorbance at 405 nm every 30 seconds for 30 minutes. Thegraphs shown are baseline-subtracted mean±SEM, n=3 for all experiments.(A) At concentrations of 100 μg/mL, PAMAM dendrimer generations 4-7 allshowed increased turbidity, indicating the induction of fibrinogenaggregates; (B) while PAMAM dendrimer generations 1-3 did not show signsof fibrinogen aggregation at 100 μg/mL, when tested at 150 μM (or 0.21,0.49, and 1.0 mg/mL respectively), generation 3 PAMAM dendrimer alsocaused detectable turbidity, indicative of inducing fibrinogenaggregation; and (C) UHRA compounds showed no detectable fibrinogenaggregation even at concentrations up to 1.5 mg/mL. (Note that 1.5 mg/mLUHRA 8 is 150 μM.).

FIG. 10 shows non-toxicity of UHRA 10 in vivo, wherein dose tolerance ofUHRA was examined in mice by the administration of 100 mg/kg, 200 mg/kgof UHRA-10 or saline control to female Balb/C mice, wherein graph (A)shows no change in the body weights (n=3, reported as mean±S.D.) of miceinjected with either saline (black circles) or UHRA 10 at doses of 100(red squares) or 200 mg/kg (blue triangles); and (B) shows that serumlactate dehydrogenase (LDH) levels in mice injected with saline or with100 or 200 mg/kg UHRA 10 were all within the normal ranges for serum LDHin mice.

FIG. 11 shows the final turbidity of matured fibrin clots produced frompurified fibrinogenin presence of UHRA 8 or PS, where even at 500 μg/mL,UHRA 8 did not increase the final turbidity in comparison to PS at 50μg/mL suggesting that fibrin polymerization is not affected in presenceof UHRA 8,****P<0.0005.

FIG. 12 shows that UHRA 8 does not alter fibrin clot morphology andfiber size, where clots were made by incubating 3 mg/mL of humanfibrinogen in the presence of 3.0 mMCaCl₂ plus UHRA 8 or PS and theclotting was initiated with 2.5 NIHU/mL of thrombin, clots were thenallowed to mature for 1 hour and then processed for scanning electronmicroscopy (SEM) imaging: (A) shows scanning electron micrographs offibrin clots formed in presence of UHRA 8 at different concentrations(50 to 500 μg/mL), where even in presence of 500 μg/mL of UHRA 8 gavesimilar clot architecture as that of the control fibrin clot with bothlow (10,000× (shown as 10×)) and high (25,000× (shown as 25×))magnifications; (B) shows scanning electron micrographs of fibrin clotsformed in presence of PS at different concentrations (25 to 100 μg/mL),where the fibrin clot formed in presence of PS even at 25 μg/mL hasstructural variations compared to the control clot; and (C) shows thatfibrin fiber thickness of the clot formed in presence of UHRA 8 or PS,where the fiber thickness is measured from scanning electron micrographsusing ImageJ software. Fibrin fibers formed in the presence of 25 μg/mLof PS are significantly thicker than the control. ***p<0.0001.

FIG. 13 shows a that blood clot characteristics remain unchanged in thepresence of UHRA 8, where clotting was initiated by recalcifying humanwhole blood with 11.1 mM CaCl₂, clot samples were then processed forscanning electron microscopy imaging , where the clots formed inpresence of UHRA 8 at 500 μg/mL did not show any major morphologicalchanges. However, abnormal clotting and clot morphology was observedgreater than 50 μg/mL of PS (images not shown) (Images were taken at twomagnifications 2.5× and 5×, respectively. However, images from only 5×magnification (5,000×) are shown. Respective scale bar is mentionedbelow the image.)

FIG. 14 shows biodistribution in female Balb/C mice after intravenousand subcutaneous administration of 20 mg/kg of tritiated UHRA-10, basedon radioactivity in blood (A) and plasma (B). Due to the low molecularweight and smaller size of UHRA-10, the polymer is rapidly cleared fromthe circulation.

FIG. 15 shows the biodistribution in female Balb/C mice afterintravenous and subcutaneous administration of 20 mg/kg of tritiatedUHRA-10. The radioactivity in the liver (A), spleen (B), kidneys (C),lungs (D) and heart (E), which shows very low accumulation of UHRA-10(10% of the injected dose) in liver, (5-7% of the injected dose) inspleen and <5% in kidneys, lungs and heart.

FIG. 16A shows a thromboelastograph trace obtained after performingwhole blood TEG analysis with nucleic acid and UHRA-8.

FIG. 16B shows the coagulation time parameter obtained from TEGanalysis, where the incubation of nucleic acid with whole blood reducedthe clotting time demonstrating the prothrombotic potential of isolatednucleic acid, but clotting time was normalized in the presence of UHRA-8demonstrating the inhibition of prothrombotic activity of nucleic acidby UHRA molecule.

DETAILED DESCRIPTION

Polyphosphate (polyP) is secreted by activated platelets and has beenshown to contribute to thrombosis, suggesting that it could be a novelantithrombotic target. Previously reported polyP inhibitors based onpolycationic substances such as polyethylenimine (PEI), polyamidoamine(PAMAM) dendrimers and polymyxin B, while attenuating thrombosis, allhave significant toxicity in vivo, likely due to the presence ofmultiple primary amines responsible for their polyP binding ability.Herein, a novel class of non-toxic polycationic polymers were examined.The polymers were initially designed as Universal Heparin ReversalAgents (UHRAs), but were tested herein for their ability to block polyPprocoagulant activity and therefore, their utility as antithrombotictreatments. Several UHRA compounds strongly inhibited polyP procoagulantactivity in vitro and four were selected for further examination inmouse models of thrombosis and hemostasis. Compounds UHRA 9 and UHRA 10reduced arterial thrombosis in mice and were as effective as heparin. Inmouse tail bleeding tests, administration of UHRA 9 or UHRA 10 wasassociated with significantly less bleeding compared to therapeuticallyequivalent doses of heparin. Thus, these compounds offer a new platformfor developing novel antithrombotic agents that target procoagulantanionic polymers like polyP with reduced toxicity and bleeding sideeffects.

Recently a family of dendritic polymer-based universal heparin reversalagents (UHRA) were developed as synthetic antidotes to all heparin-basedanticoagulants (33, 34). These UHRAs were designed by assemblingmultifunctional cationic groups into the core of a dendritic polymer,which are then shielded from non-specific interactions with bloodcomponents using a protective layer of short-chain polyethylene glycol(PEG). The binding of UHRA to anionic heparins is optimized by thearrangement of cationic groups and the size of the polymer scaffold.Specific UHRA compounds showed high binding affinity to various heparinsand neutralized their anticoagulant activity while exhibiting excellentblood compatibility and non-toxicity in vivo that is not usuallyobserved with conventional cationic polymers (33).

While the development and synthesis of UHRA compounds allowed theidentification of important new heparin reversal agents, we alsorealized that within the UHRA family of compounds we might find polymerstructures that could function as non-toxic polyP inhibitors. Theextremely low toxicity, coupled with the ease with which their chemicalcomposition and pharmacological properties can be varied, made the UHRAcompounds ideal candidates for testing and developing this novel classof antithrombotic agents targeting polyP. As described herein there wasa successful identification of UHRA compounds with high affinity forpolyP in vitro, and which also interrupt thrombosis in vivo.

Without wishing to be bound by any particular theory, there can bediscussion herein of beliefs or understandings of underlying principlesor mechanisms relating to embodiments of the disclosure. It isrecognized that regardless of the ultimate correctness of anyexplanation or hypothesis, an embodiment of the disclosure cannonetheless be operative and useful.

The foregoing and other objects and features of the disclosure willbecome more apparent from the following detailed description, whichproceeds with reference to the accompanying figures.

Further embodiments, forms, features, aspects, benefits, objects, andadvantages of the present application shall become apparent from thedetailed description and figures provided herewith.

Definitions

A ‘nucleic acid molecule’ as used herein is meant to be a single- ordouble-stranded linear polynucleotide containing eitherdeoxyribonucleotides or ribonucleotides that are linked by3′-5′-phosphodiester bonds.

An ‘outer shell’ as used herein is meant to be a ‘hydrophilic polymericsystem’. Such an outer shell would generally be pharmaceuticallyacceptable and biocompatible, especially where a polymer is foradministration to a subject or for the purification of or extractionfrom a biological fluid (for example, blood). A ‘hydrophilic polymericsystem’ as used herein is meant to encompass most any polyether orpolyalcohol. Examples of such polyethers and polyalcohols are lowmolecular weight polyglycerol, linear polyglycerol, oligosaccharides,poly(N-isopropylacrylamide(PNIPAM), polyacrylamide (PAM),poly(2-oxazoline), poly(ethylene glycol), methoxy (polyethylene glycol),poly(ethylene oxide), poly(vinyl alcohol) (PVA), orpoly(vinylpyrrolidone) (PVP) or other water soluble polymers or acombination thereof. Specific examples may be PEG, PEG-OH and PEG-OMe.Specific examples, may also be

wherein n is 0-100, x is 0-100 and y is 0-100.

The outer shell polymer density of a compound may be given as a wt %.For example, most of the exemplified compounds have PEG by weight in therange 60-75 wt %. However, the useful range may be anywhere from 10 to90 wt %.

As shown in FIG. 1B, the R group (R) or the binding group may berepresented in different ways. Structure I is the actual structure ofthe binding group, and II is the same structure at physiological pH (pH7.4) when the tertiary amine groups get protonated giving rise to acationic molecule. The cationic molecule is able to bind to negativelycharged (anionic) molecules or macromolecules.

A ‘sample’ as used herein is meant to include a representative part of alarger whole, a complete extract or majority portion of the largerwhole, a group of samples pooled from a number of sources, wherein thepooled sample may include a complete extract or majority portionthereof, or representative part of a larger whole or combinationsthereof. For example, the sample may be used for the extraction ofphosphate containing biological macromolecule, wherein the sample is apooled blood sample.

As used herein ‘neutralize’ is to counteract the activity or effect of agiven entity, in whole or in part. The neutralization, may be reversibleand the neutralization may be total (for example, excluding all possiblebinding partners) or may be partial (for example, excluding one or a fewbinding partners). For example, neutralization, may result in theblocking one or more particular binding partners to the entity beingneutralized or may be specific to one or more binding partners and notbind to the entity being neutralized at all.

As used herein, the term ‘treatment’ means to treat, prevent, orotherwise ameliorate the symptoms or underlying cause of a disease,syndrome, or condition. Treatment may include administering atherapeutically beneficial pharmaceutical composition, and the timing ofsuch treatment may vary. For instance, treatment may occur prior to thepresentation of symptoms, during the onset of symptoms, or after thefull development of symptoms. Treatment may include acute treatmentregimens, for instance only one or a few doses. Treatment may includechronic treatment regimens, for instance regular or irregular repeateddoses over a longer term, which may include repeated doses over theentire lifetime of a subject. Treatment may include administering atherapeutically beneficial pharmaceutical composition to a subject witha confirmed diagnosis of having a disease, syndrome, or condition.Treatment may include administering a therapeutically beneficialpharmaceutical composition to a subject who is suspected of having adisease, syndrome, or condition. Treatment may include administering atherapeutically beneficial pharmaceutical composition to a subject atrisk of having a disease, syndrome, or condition.

Compounds as described herein may be in the free form or in the form ofa salt thereof. In some embodiment, compounds as described herein may bein the form of a pharmaceutically acceptable salt, which are known inthe art (Berge S. M. et al., J. Pharm. Sci. (1977) 66(1):1-19).Pharmaceutically acceptable salt as used herein includes, for example,salts that have the desired pharmacological activity of the parentcompound (salts which retain the biological effectiveness and/orproperties of the parent compound and which are not biologically and/orotherwise undesirable). Compounds as described herein having one or morefunctional groups capable of forming a salt may be, for example, formedas a pharmaceutically acceptable salt. Compounds containing one or morebasic functional groups may be capable of forming a pharmaceuticallyacceptable salt with, for example, a pharmaceutically acceptable organicor inorganic acid. Pharmaceutically acceptable salts may be derivedfrom, for example, and without limitation, acetic acid, adipic acid,alginic acid, aspartic acid, ascorbic acid, benzoic acid,benzenesulfonic acid, butyric acid, cinnamic acid, citric acid,camphoric acid, camphorsulfonic acid, cyclopentanepropionic acid,diethylacetic acid, digluconic acid, dodecylsulfonic acid,ethanesulfonic acid, formic acid, fumaric acid, glucoheptanoic acid,gluconic acid, glycerophosphoric acid, glycolic acid, hemisulfonic acid,heptanoic acid, hexanoic acid, hydrochloric acid, hydrobromic acid,hydriodic acid, 2-hydroxyethanesulfonic acid, isonicotinic acid, lacticacid, malic acid, maleic acid, malonic acid, mandelic acid,methanesulfonic acid, 2-napthalenesulfonic acid, naphthalenedisulphonicacid, p-toluenesulfonic acid, nicotinic acid, nitric acid, oxalic acid,pamoic acid, pectinic acid, 3-phenyipropionic acid, phosphoric acid,picric acid, pimelic acid, pivalic acid, propionic acid, pyruvic acid,salicylic acid, succinic acid, sulfuric acid, sulfamic acid, tartaricacid, thiocyanic acid or undecanoic acid. Compounds containing one ormore acidic functional groups may be capable of forming pharmaceuticallyacceptable salts with a pharmaceutically acceptable base, for example,and without limitation, inorganic bases based on alkaline metals oralkaline earth metals or organic bases such as primary amine compounds,secondary amine compounds, tertiary amine compounds, quaternary aminecompounds, substituted amines, naturally occurring substituted amines,cyclic amines or basic ion-exchange resins. Pharmaceutically acceptablesalts may be derived from, for example, and without limitation, ahydroxide, carbonate, or bicarbonate of a pharmaceutically acceptablemetal cation such as ammonium, sodium, potassium, lithium, calcium,magnesium, iron, zinc, copper, manganese or aluminum, ammonia,benzathine, meglumine, methylamine, dimethylamine, trimethylamine,ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine,tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol,2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine,caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine,glucamine, methylglucamine, theobromine, purines, piperazine,piperidine, procaine, N-ethylpiperidine, theobromine,tetramethylammonium compounds, tetraethylammonium compounds, pyridine,N,N-dimethylaniline, N-methylpiperidine, morpholine, N-methylmorpholine,N-ethylmorpholine, dicyclohexylamine, dibenzylamine,N,N-dibenzylphenethylamine, ephenamine, N,N′-dibenzylethylenediamine orpolyamine resins. In some embodiments, compounds as described herein maycontain both acidic and basic groups and may be in the form of innersalts or zwitterions, for example, and without limitation, betaines.Salts as described herein may be prepared by conventional processesknown to a person skilled in the art, for example, and withoutlimitation, by reacting the free form with an organic acid or inorganicacid or base, or by anion exchange or cation exchange from other salts.Those skilled in the art will appreciate that preparation of salts mayoccur in situ during isolation and purification of the compounds orpreparation of salts may occur by separately reacting an isolated andpurified compound.

In some embodiments, compounds and all different forms thereof (e.g.free forms, salts, polymorphs, isomeric forms) as described herein maybe in the solvent addition form, for example, solvates. Solvates containeither stoichiometric or non-stoichiometric amounts of a solvent inphysical association the compound or salt thereof. The solvent may be,for example, and without limitation, a pharmaceutically acceptablesolvent. For example, hydrates are formed when the solvent is water oralcoholates are formed when the solvent is an alcohol.

In some embodiments, compounds and all different forms thereof (e.g.free forms, salts, solvates, isomeric forms) as described herein mayinclude crystalline and amorphous forms, for example, polymorphs,pseudopolymorphs, conformational polymorphs, amorphous forms, or acombination thereof. Polymorphs include different crystal packingarrangements of the same elemental composition of a compound. Polymorphsusually have different X-ray diffraction patterns, infrared spectra,melting points, density, hardness, crystal shape, optical and electricalproperties, stability and/or solubility. Those skilled in the art willappreciate that various factors including recrystallization solvent,rate of crystallization and storage temperature may cause a singlecrystal form to dominate.

In some embodiments, compounds and all different forms thereof (e.g.free forms, salts, solvates, polymorphs) as described herein includeisomers such as geometrical isomers, optical isomers based on asymmetriccarbon, stereoisomers, tautomers, individual enantiomers, individualdiastereomers, racemates, diastereomeric mixtures and combinationsthereof, and are not limited by the description of the formulaillustrated for the sake of convenience.

In some embodiments, pharmaceutical compositions as described herein maycomprise a salt of such a compound, preferably a pharmaceutically orphysiologically acceptable salt. Pharmaceutical preparations willtypically comprise one or more carriers, excipients or diluentsacceptable for the mode of administration of the preparation, be it byinjection, inhalation, topical administration, lavage, or other modessuitable for the selected treatment. Suitable carriers, excipients ordiluents (used interchangeably herein) are those known in the art foruse in such modes of administration.

Suitable pharmaceutical compositions may be formulated by means known inthe art and their mode of administration and dose determined by theskilled practitioner. For parenteral administration, a compound may bedissolved in sterile water or saline or a pharmaceutically acceptablevehicle used for administration of non-water soluble compounds such asthose used for vitamin K. For enteral administration, the compound maybe administered in a tablet, capsule or dissolved in liquid form. Thetablet or capsule may be enteric coated, or in a formulation forsustained release. Many suitable formulations are known, including,polymeric or protein microparticles encapsulating a compound to bereleased, ointments, pastes, gels, hydrogels, or solutions which can beused topically or locally to administer a compound. A sustained releasepatch or implant may be employed to provide release over a prolongedperiod of time. Many techniques known to one of skill in the art aredescribed in Remington: the Science & Practice of Pharmacy by AlfonsoGennaro, 20^(th) ed., Lippencott Williams & Wilkins, (2000).Formulations for parenteral administration may, for example, containexcipients, polyalkylene glycols such as polyethylene glycol, oils ofvegetable origin, or hydrogenated naphthalenes. Biocompatible,biodegradable lactide polymer, lactide/glycolide copolymer, orpolyoxyethylene-polyoxypropylene copolymers may be used to control therelease of the compounds. Other potentially useful parenteral deliverysystems for modulatory compounds include ethylene-vinyl acetatecopolymer particles, osmotic pumps, implantable infusion systems, andliposomes. Formulations for inhalation may contain excipients, forexample, lactose, or may be aqueous solutions containing, for example,polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may beoily solutions for administration in the form of nasal drops, or as agel.

Compounds or pharmaceutical compositions as described herein or for useas described herein may be administered by means of a medical device orappliance such as an implant, catheter, graft, prosthesis, stent, etc.Also, implants may be devised which are intended to contain and releasesuch compounds or compositions. An example would be an implant made of apolymeric material adapted to release the compound over a period oftime. Furthermore, the compounds described herein may be immobilized ona ‘support’ to be used to filter a biological or other fluid, or toextract a phosphate containing biological macromolecule or to extract ananionic biological macromolecule.

An ‘effective amount’ of a pharmaceutical composition as describedherein includes a therapeutically effective amount or a prophylacticallyeffective amount. A ‘therapeutically effective amount’ refers to anamount effective, at dosages and for periods of time necessary, toachieve the desired therapeutic result, such as reduced tumor size,increased life span or increased life expectancy. A therapeuticallyeffective amount of a compound may vary according to factors such as thedisease state, age, sex, and weight of the subject, and the ability ofthe compound to elicit a desired response in the subject. Dosageregimens may be adjusted to provide the optimum therapeutic response. Atherapeutically effective amount is also one in which any toxic ordetrimental effects of the compound are outweighed by thetherapeutically beneficial effects. A ‘prophylactically effectiveamount’ refers to an amount effective, at dosages and for periods oftime necessary, to achieve the desired prophylactic result, such asreduced thrombosis, increased life span, increased life expectancy orprevention of the progression of disease. Typically, a prophylactic doseis used in subjects prior to or at an earlier stage of disease, so thata prophylactically effective amount may be less than a therapeuticallyeffective amount.

It is to be noted that dosage values may vary with the severity of thecondition to be alleviated. For any particular subject, specific dosageregimens may be adjusted over time according to the individual need andthe professional judgment of the person administering or supervising theadministration of the compositions. Dosage ranges set forth herein areexemplary only and do not limit the dosage ranges that may be selectedby medical practitioners. The amount of active compound(s) in thecomposition may vary according to factors such as the disease state,age, sex, and weight of the subject. Dosage regimens may be adjusted toprovide the optimum therapeutic response. For example, a single bolusmay be administered, several divided doses may be administered over timeor the dose may be proportionally reduced or increased as indicated bythe exigencies of the therapeutic situation. It may be advantageous toformulate parenteral compositions in dosage unit form for ease ofadministration and uniformity of dosage.

In some embodiments, compounds and all different forms thereof asdescribed herein may be used, for example, and without limitation, incombination with other treatment methods for at least one indicationselected from the group consisting of: stroke, acute coronary syndrome(for example, myocardial infarction (MI) or acute myocardial infarction(AMI)), pulmonary embolism, atrial fibrillation, venous or arterialthromboembolism, disseminated intravascular coagulation (DIC), sepsis,septic shock, Systemic Inflammatory Response Syndrome (SIRS), deep-veinthrombosis (DVT), peripheral artery disease, trauma-inducedcoagulopathy, extracorporeal circulation, cancer-associated thrombosisand inflammation. For example, compounds and all their different formsas described herein may be used as neoadjuvant (prior), adjunctive(during), and/or adjuvant (after) therapy with surgery or othertherapies.

In general, compounds as described herein should be used without causingsubstantial toxicity. Toxicity of the compounds as described herein canbe determined using standard techniques, for example, by testing in cellcultures or experimental animals and determining the therapeutic index,i.e., the ratio between the LD50 (the dose lethal to 50% of thepopulation) and the LD100 (the dose lethal to 100% of the population).In some circumstances however, such as in severe disease conditions, itmay be appropriate to administer substantial excesses of thecompositions. Some compounds as described herein may be toxic at someconcentrations. Titration studies may be used to determine toxic andnon-toxic concentrations. Toxicity may be evaluated by examining aparticular compound's or composition's specificity across cell lines.Animal studies may be used to provide an indication if the compound hasany effects on other tissues.

Compounds as described herein may be administered to a subject. As usedherein, a ‘subject’ may be a human, non-human primate, rat, mouse, cow,horse, pig, sheep, goat, dog, cat, etc. The subject may be suspected ofhaving or at risk for having one or more of stroke, acute coronarysyndrome (for example, myocardial infarction (MI) or acute myocardialinfarction (AMI)), pulmonary embolism, atrial fibrillation, venous orarterial thromboembolism, disseminated intravascular coagulation (DIC),sepsis, septic shock, Systemic Inflammatory Response Syndrome (SIRS),deep-vein thrombosis (DVT), peripheral artery disease, trauma-inducedcoagulopathy, extracorporeal circulation, cancer-associated thrombosisand inflammation.

Pharmaceutical Dosage Forms

The following formulations illustrate representative pharmaceuticaldosage forms that may be used for the therapeutic or prophylacticadministration of a compound of a formula described herein, a compoundspecifically disclosed herein, or a pharmaceutically acceptable salt orsolvate thereof (hereinafter referred to as ‘Compound X’):

(i) Tablet 1 mg/tablet ‘Compound X’ 100.0 Lactose 77.5 Povidone 15.0Croscarmellose sodium 12.0 Microcrystalline cellulose 92.5 Magnesiumstearate 3.0 300.0

(ii) Tablet 2 mg/tablet ‘Compound X’ 20.0 Microcrystalline cellulose410.0 Starch 50.0 Sodium starch glycolate 15.0 Magnesium stearate 5.0500.0

(iii) Capsule mg/capsule ‘Compound X’ 10.0 Colloidal silicon dioxide 1.5Lactose 465.5 Pregelatinized starch 120.0 Magnesium stearate 3.0 600.0

(iv) Injection 1 (1 mg/mL) mg/mL ‘Compound X’ (free acid form) 1.0Dibasic sodium phosphate 12.0 Monobasic sodium phosphate 0.7 Sodiumchloride 4.5 1.0N Sodium hydroxide solution q.s. (pH adjustment to7.0-7.5) Water for injection q.s. ad 1 mL

(v) Injection 2 (10 mg/mL) mg/mL ‘Compound X’ (free acid form) 10.0Monobasic sodium phosphate 0.3 Dibasic sodium phosphate 1.1 Polyethyleneglycol 400 200.0 0.1N Sodium hydroxide solution q.s. (pH adjustment to7.0-7.5) Water for injection q.s. ad 1 mL

(vi) Aerosol mg/can ‘Compound X’ 20 Oleic acid 10Trichloromonofluoromethane 5,000 Dichlorodifluoromethane 10,000Dichlorotetrafluoroethane 5,000

(vii) Topical Gel 1 wt. % ‘Compound X’   5% Carbomer 934 1.25%Triethanolamine q.s. (pH adjustment to 5-7) Methyl paraben  0.2%Purified water q.s. to 100 g

(viii) Topical Gel 2 wt. % ‘Compound X’ 5% Methylcellulose 2% Methylparaben 0.2%  Propyl paraben 0.02%   Purified water q.s. to 100 g

(ix) Topical Ointment wt. % ‘Compound X’ 5% Propylene glycol 1%Anhydrous ointment base 40%  Polysorbate 80 2% Methyl paraben 0.2% Purified water q.s. to 100 g

(x) Topical Cream 1 wt. % ‘Compound X’ 5% White bees wax 10%  Liquidparaffin 30%  Benzyl alcohol 5% Purified water q.s. to 100 g

(xi) Topical Cream 2 wt. % ‘Compound X’ 5% Stearic acid 10%  Glycerylmonostearate 3% Polyoxyethylene stearyl ether 3% Sorbitol 5% Isopropylpalmitate 2% Methyl Paraben 0.2%  Purified water q.s. to 100 g

These formulations may be prepared by conventional procedures well knownin the pharmaceutical art. It will be appreciated that the abovepharmaceutical compositions may be varied according to well-knownpharmaceutical techniques to accommodate differing amounts and types ofactive ingredient ‘Compound X’. Aerosol formulation (vi) may be used inconjunction with a standard, metered dose aerosol dispenser.Additionally, the specific ingredients and proportions are forillustrative purposes. Ingredients may be exchanged for suitableequivalents and proportions may be varied, according to the desiredproperties of the dosage form of interest.

Materials and Methods

Chemicals were from Sigma-Aldrich™ and used without further purificationunless mentioned. Glycidol was purified by distillation under reducedpressure before use and stored over molecular sieves at 4° C. ¹H nuclearmagnetic resonance spectra were acquired in deuterium oxide on a BrukerAvance AV-300 spectrometer. Absolute molecular weights of the polymerswere determined by Gel Permeation Chromatography (GPC) on a Waters 2695™separation module fitted with a DAWN EOS multiangle laser lightscattering (MALLS) detector coupled with Optilab DSP™ refractive indexdetector, both from Wyatt Technology™. GPC analysis was performed usingWatersTM ultrahydrogel columns (guard, linear and 120) and 0.1 M NaNO₃(10 mM phosphate buffer) as the mobile phase.

Synthesis of UHRA 10

The polymer scaffolds of this family of UHRA compounds were synthesizedby anionic ring-opening polymerization of glycidol and a-methoxy-v-epoxypolyethylene glycol (mPEG-400), which were then postfunctionalized tointroduce positively charged groups based on branched tertiary amines.Detailed synthetic methods are provided below and described inpublications (33, 34).

In the first step, a HPG-PEG polymer was synthesized as follows: Athree-necked round bottomed flask was cooled under vacuum and filledwith argon. To this, 1,1,1-tris(hydroxymethyl)propane (TMP, 0.240 g) andpotassium methylate (25 wt % solution in methanol, 0.220 mL) were addedand stirred for 30 minutes. Methanol was removed under vacuum for 4hours. The flask was heated to 95° C. and glycidol (2.5 mL) was addedover a period of 15 hours. After complete addition of monomer, thereaction mixture was stirred for additional 3 hours. mPEG-epoxide400 (9mL) was added over a period of 12 hours. The reaction mixture wasstirred for additional 4 hours. The polymer was dissolved in methanol,and twice precipitated from diethyl ether. The polymer was dissolved inwater and dialyzed against water using MWCO-1000 membrane for 3 dayswith periodic changes in water. Yield: 80%. ¹H NMR (CDCl₃, 300 MHz): δppm 3.37 (—OCH₃ from PEG), 3.4-3.95 (main chain protons from HPG andPEG). PEG content: 35 mol %; Polyglycerol: 65 mol %; GPC-MALLS (0.1 MNaNO₃): Mn 10000; Mw/Mn 1.7.

The HPG-PEG-iokDa precursor polymer (2.4 g) was then dissolved in 25 mLof pyridine. To this, p-toluenesulfonyl chloride (8 g) was added andstirred at room temperature for 24 hours. Pyridine was removed by rotaryevaporation; the polymer was dissolved in 0.1 N HCl and dialyzedovernight. The HPG-PEG-tosylate was isolated by freeze drying. TheHPG-PEG-tosylate (2.8 g) and tris (2-aminoethylamine) (8 mL) weredissolved in 1,4-dioxane (25 mL) and refluxed for 24 hours. Dioxane wasremoved under vacuum and the polymer was dissolved in minimum amount ofmethanol and precipitated twice from diethyl ether. The polymer was thendissolved in water and dialyzed against water using MWCO-1000 membranefor 2 days. The resulting polymer solution was added to a mixture offormaldehyde (6 mL) and formic acid (6 mL) at 0° C. The reaction mixturewas refluxed overnight. After cooling to room temperature, the pH of thesolution was adjusted to 10 using NaOH and the polymer was extractedwith dichloromethane. Dichloromethane was removed under vacuum; thepolymer dissolved in distilled water and dialyzed against water usingMWCO-1000 membrane with frequent changes in water for 2 days. The numberof binding groups in UHRA 10 (by conductometric titration) wascalculated to be 11. ¹H NMR (CDCl₃, 300 MHz): δ ppm 2.27 (—NCH₃),2.4-2.7 (—N—CH₂—), 3.38 (—OCH₃ from PEG), 3.4-3.95 (main chain protonsfrom HPG and PEG).

The other UHRAs were synthesized using a similar procedure as outlineabove. HPG-PEG polymer having respective molecular weight wassynthesized in the first step and the amount of reagents in thepost-functionalization step was varied to obtain different number ofbinding groups on the UHRAs. The molecular weight and number of bindinggroups of different UHRAs are given in TABLE 2. The structure of theother UHRAs is similar to the one shown in FIG. 1A, with differences inthe number of glycerol units of the polymer (—O—CH₂—CH(O)—CH₂—O—), PEGunits and the number of R groups. The ‘R’ groups are distributedrandomly within the polymeric structure. The number of glycerol and PEGunits per UHRA increases with molecular weight of the construct.

All the UHRAs were synthesized using a similar procedure as thatdescribed for UHRA 10 in the main description above. In the first step,HPG-PEG polymer of the respective molecular weight was prepared and theproportion of the reagents in the post functionalization step was variedto introduce different number of polyP-binding groups (R) on UHRAs. Thecharacteristics of the UHRAs are given below. The number of bindinggroups on UHRAs was determined by conductometric titration.

Characterization of UHRAs

UHRA 1: HPG-PEG polymer: PEG content: 35 mol %; Polyglycerol: 65 mol %;GPC-MALLS (0.1 M NaNO₃): Mn 116000 g/mol; Mw/Mn 1.2. Number ofpolyP-binding groups per polymer: 33.

UHRA 2: HPG-PEG polymer: PEG content: 33 mol %; Polyglycerol: 67 mol %;GPC-MALLS (0.1 M NaNO₃): Mn 48000 g/mol; Mw/Mn 1.45. Number ofpolyP-binding groups per polymer: 18.

UHRAs 3 to 8: HPG-PEG polymer: PEG content: 35 mol %; Polyglycerol: 65mol %; GPC-MALLS (0.1 M NaNO₃): Mn 23000 g/mol; Mw/Mn 1.52. The numberof polyP-binding groups per polymer was 4, 5, 11, 16, 20 and 24 forUHRAs 3, 4, 5, 6, 7, and 8 respectively.

UHRA 9: HPG-PEG polymer: PEG content: 32 mol %; Polyglycerol: 68 mol %;GPC-MALLS (0.1 M NaNO₃): Mn 16000 g/mol; Mw/Mn 1.8. Number ofpolyP-binding groups per polymer: 16.

UHRA 11: HPG-PEG polymer: PEG content: 34 mol %; Polyglycerol: 66 mol %;GPC-MALLS (0.1 M NaNO₃): Mn 9400 g/mol; Mw/Mn 1.34. Number ofpolyP-binding groups per polymer: 8.

UHRAs 12, 13 and 14: HPG-PEG polymer: PEG content: 28 mol %;Polyglycerol: 72 mol %; GPC-MALLS (0.1 M NaNO₃): Mn 10000 g/mol; Mw/Mn1.41. Number of polyP-binding groups per polymer was 2, 5 and 7respectively in UHRA 12,13 and 14.

UHRAs 15 and 16: HPG-PEG polymer: PEG content: 32 mol %; Polyglycerol:68 mol %; GPC-MALLS (0.1 M NaNO₃): Mn 4900 g/mol; Mw/Mn 1.4.Number ofpolyP-binding groups per polymer was 2 and 1 respectively in UHRA 15 andUHRA 16.

In Vitro Studies

UHRA Biocompatibility Studies

Blood from healthy consented donors was either collected into 3.8%sodium citrate tube with a blood/anticoagulant ratio of 9:1 or serumtube at Centre for Blood Research, University of British Columbia. Theprotocol was approved by the University of British Columbia clinicalethical committee and written consent was obtained from each individualdonor. Platelet-rich plasma (PRP) was prepared by centrifuging citratedwhole blood samples at 150×g for 10 min in an Allegra X-22R™ Centrifuge(Beckman Coulter™, Canada). Serum was prepared by centrifuging the bloodcollected in serum tube at 1200×g for 30 min one hour after bloodcollection.

Platelet Activation

The level of platelet activation after exposure to polyP inhibitors wasquantified by flow cytometry. Ninety microliters of platelet rich plasma(PRP) was incubated at 37° C. with 10 μL of either 10 mg/mL or 20 mg/mLof UHRA, protamine or PEI stock solution (final polymer concentration 1mg/mL and 2 mg/mL respectively) in PBS. After 1 h, aliquots of theincubation mixtures were removed for assessment of the plateletactivation state. Five microliters of post-incubation platelet/polymermixture, diluted in PBS buffer, was incubated for 20 minutes in the darkwith 5 μL of phycoerythrin (PE)-labeled monoclonal anti-CD62P-PE(ImmunotechTM, Catalog No. PN IM1759U, CLB-Thromb/6 clone and Mouse IgG1isotype). The samples were then stopped with 0.3 mL ofphosphate-buffered saline solution. The level of platelet activation wasanalyzed in a BD FACSCanto II flow cytometer (Becton Dickinson™) bygating platelets specific events based on their forward scatteringprofile (size of individual platelet). Activation of platelets wasexpressed as the percentage of platelet activation marker CD62-PEfluorescence detected in the 10,000 total events counted. Bovinethrombin (1 IU/mL, Sigma) was used as the positive control, andPE-conjugated goat anti-mouse IgG polyclonal antibodies (ImmunotechTM)were used as the non-specific binding control. PRP from three differentdonors was used for the analysis and each sample was run in duplicates,the average values (±SD) are reported.

Complement Activation

The level of complement activation after exposure to polyP inhibitorswas measured by CH₅₀ sheep erythrocyte complement lysis assay in humanserum. Stock solutions of UHRA, PEI and protamine at concentrations of10 mg/mL and 20 mg/mL were prepared in PBS. Ten microliters of the stocksolution was mixed with 90 μL of GVB2+ buffer (0.1% gelatin, 5 mMVeronal, 145 mM NaCl, 0.025% NaN₃ with 0.15 mM CaCl₂ and 0.5 mM MgCl₂,pH 7.3, CompTech™) diluted human serum for 1 hour at 37° C. (finalpolymer concentration of 1 mg/mL or 2 mg/mL). Heat-aggregated human IgG(1 mg/mL) and PBS were used as positive and negative controls,respectively. After 1 hour, 60 μI, of post-incubation serum/polymermixture was diluted by the addition of 120 μL of GVB2+ buffer. Seventyfive microliters of GVB2+ diluted serum/UHRA or serum/protamine mixturewas incubated for 1 h at 37° C. with 75 μL of Ab-sensitized sheeperythrocyte (CompTech). The reaction was stopped by addition of 300 μLcold GVB-EDTA to each sample. Intact Ab-sensitized sheep erythrocyteswere then spun down at 8000 rpm for 3 min and the supernatants weresampled. Percentage sheep erythrocyte lysis was calculated using averageabsorbance values as follows: % lysis=(Abs540, test sample−Abs540,blank)/(Abs540, 100% lysis−Abs540, blank)×100. Percentage of complementactivated (consumed) by the UHRA or protamine sulfate was expressed as:100−% lysis.

Inhibition of Thrombin Binding to PolyP

Streptavidin coated 96 well plates (Corning™) were incubated with 20 μMbiotinylated polyP (monomer concentration, prepared as publishedpreviously (29)) diluted in 50 mM Tris-HCl pH 7.4, 1% BSA, 0.05% NaN₃,and 0.05% Tween 20 for 3 hours at room temperature. The wells were thenwashed with 1 M LiCl and water and incubated with 40 nM bovinea-thrombin (Enzyme Research Laboratories™) plus varying concentrationsof UHRA inhibitors in 20 mM Hepes NaOH pH 7.4, 50 mM NaCl, 1.4 mM CaCl₂,0.5 mM MgCl₂, 0.1% BSA, 0.05% Tween-20, 0.05% NaN₃ for 1 hour at roomtemperature. After washing with 20 mM Hepes NaOH pH 7.4, 0.05% Tween-20,0.05% NaN₃, the amount of thrombin bound to polyP was quantified bymonitoring the rate of cleavage of 400 μM Sar-Pro-Arg-p-nitroanilide(Bachem™) in 20 mM Hepes NaOH pH 7.4, 0.05% NaN₃ by measuring A₄₀₅ every30 seconds for 20 minutes at room temperature in a SpectraMax™ PlateReader (Molecular Devices™)

Plasma Clotting Assays

Plasma clotting times were quantified at 37° C. using a STart4™coagulometer (Diagnostica Stago™). All clotting assays used finalconcentrations of 33% pooled normal plasma (George King Bio-Medical™),25 μM liposomes (70:30 ratio of phosphatidylcholine tophosphatidylserine), 41.7 mM imidazole pH 7.0 and 8.33 mM CaCl₂. Theclotting assays were initiated by mixing the activator (polyP orpolyguanylic acid) with inhibitor, liposomes, and prewarmed plasma for 3minutes at 37° C. and clotting was initiated by the addition ofprewarmed CaCl₂. Activator concentrations of 10 μM long-chain polyP and25 μg/mL polyguanylic acid (RNA) were chosen to give 60-80 secondclotting times in the absence of added inhibitors.

Plasma Clot Formation and Lysis by Turbidity Analysis

Blood from healthy consented donors was collected by venipuncture undera protocol approved by the University of British Columbia clinicalethical committee and written consent was obtained from each individualdonor. Platelet-poor plasma (PPP) was prepared by centrifuging citratedwhole blood samples at 1000×g for 15 minutes. All plasma clotting andlysis experiments were performed in a clear flat-bottomed 96-wellmicroplate (Costar™) at 37° C. Turbidimetric plasma clotting assays wereperformed with PPP obtained from three different donors (N=3).

Clotting was initiated in 85 μL of diluted platelet-poor plasma (PPP)mixed with 5 μL of buffer, protamine sulphate or UHRA 8 (dilution 1:20),by the addition of 5 μL of recombinant tissue factor (Innovin™(1:10,000) and 5 μL of CaCl2 (20 mM). Clot formation was monitored bythe changes in absorbance at 405 nm every 30 seconds on a SpectramaxVMAX™ plate reader (Molecular Devices™), for 2 hours. Clotting of PPP byrecalcification was performed in a similar way as described above in theabsence of tissue factor. UHRA 8 or protamine concentrations were asshown. Clotting parameters such as lag time and maximum absorbance(MaxAbs™) were calculated. Lag time is considered as the time point whenan exponential increase in absorbance was observed due to protofibrilformation. MaxAbs™ is the absorbance at which at least 5 readings wereidentical (plateau phase, corrected for the lag time).

The lysis of tissue factor-induced plasma clots formed in presence ofUHRA 8 or PS exposed to exogenous tissue plasminogen activator (t-PA)was monitored by the microplate turbidimetric assay. Clot lysisexperiments were performed in normal control pooled plasma collectedfrom 20 donors (Affinity Biologicals™). Diluted plasma (85 μL) spikedwith the UHRA 8 or protamine (dilution 1:10), 5 μL of recombinant tissuefactor (Innovin™ (1:10,000)), 5 μL of t-PA (25 ng/mL) and 5 μL of CaCl2(20 mM) was added to microplate wells. All concentrations are final. Thechanges in optical density at 405 nm was monitored every 30 seconds for30 minutes (clot formation), and then every 1 minute thereafter up to300 minutes at 37° C. Clot lysis half time (CLT50) was defined as themid-point of the lysis curve excluding the plateau phase and the cleartransition. The area under the clot lysis curve is a measure of clotformation time, clot density and lysis potential was calculated byapplying trapezoid rule to curve points generated after baseline (lowestabsorbance value) subtraction. All analysis was done with GraphPad™prism 6.0.

Isothermal Titration Calorimetry (ITC)

Binding studies were performed using a VP-ITC microcalorimeter fromMicrocal, Inc.™ (Northampton, Mass.) with a cell volume of 1.4 mL at298K. PolyP (PolyP₇₅) and UHRA solutions used for titrations wereprepared in 10 mM phosphate buffered saline (0.137 M NaCl, pH 7.4).Samples were filtered using 0.2 μm filters and degassed prior toaddition. Injections of 10 μl of UHRA (300 μM) solution were performedfrom a computer controlled microsyringe at an interval of 5 minutes into5 μM (estimated polymer concentration based on average polymer size of75 phosphates) polyP solution in the cell. The heats of dilution fromtitrations of UHRA solution into buffer only (without polyP) weresubtracted from the heats obtained from titrations of UHRA solution intopolyP solution to obtain net binding heats. All the experiments werecarried out in duplicate. Raw ITC data of UHRA binding to polyP wasanalyzed with Origin™ software from Microcal, Inc.™ (Northampton,Mass.). The one-site binding model was used to fit the isotherms by anonlinear least-squares analysis.

Scanning Electron Microscopy of Fibrin and Whole Blood Clots

The morphology of clots formed in presence of UHRA and protamine wasdetermined by scanning electron microscopy (SEM) analysis. All samplesfor SEM were randomly coded and blinded to the individual performingimaging and analysis to avoid bias. Fibrin clots were formed in sterileround-bottomed 5 mL polypropylene tubes (BD Falcon) by mixing purifiedhuman fibrinogen (200 μL, 3 mg/mL) in 2omM HEPES (pH 7.4 and 150 mMNaCl) with 2.5 NIHU/mL thrombin and 3 mM CaCl2 and UHRA or protamine (inHEPES buffer) (0-500 μg/mL). All concentrations are final. Control clotwas prepared in the absence of UHRA or protamine. After incubating thesolution for 1 hour at 37° C., clots were immediately fixed usingkarnovsky fixative (2.5% glutaraldehyde and 4% formaldehyde) andrepeatedly washed with 0.1 M sodium cacodylate buffer (pH=7.4) followedby post-fixation with 1% v/v osmium tetroxide. The samples were washedthree times with distilled water and then dehydrated with gradientethanol series (20-95% v/v). Clots were then critical point-dried withCO₂ in a Tousimis-Autosamdri 815B™ critical point dryer, mounted ontostubs, and gold sputter-coated for SEM examination using Hitachi S-4700™field emission scanning electron microscope at 5,000× (shown as 5×),10,000× (shown as 10×) and 25,000× (shown as 25×) magnifications. Imagesof two different areas of each clot were captured. Fiber diameters ofall clots were measured with image analysis software package ImageJ™(National Institutes of Health, USA). Fiber diameter (n=30) from 8separate areas of each clot was measured and used for calculating theaverage fiber size formed.

Whole blood clots were also prepared in 5 mL polypropylene tubes (BDFalcon) by recalcifying 180 μL of whole blood with 20 μL of 11.1 mMCaCl2 (final) in the absence or presence of UHRA/protamine in 20 mMHEPES, pH 7.4, 150 mM NaCl at 37° C. Whole blood clots were thencarefully processed for SEM imaging as described for fibrin clots.

Nucleic Acid Coagulation Assays

Blood was collected from healthy consented donors into 3.8% sodiumcitrate tube with a blood/anticoagulant ratio of 9:1 at the Centre forBlood Research, University of British Columbia. Nucleic acid wasisolated from blood using QIAampTM DNA blood mini kit. The integrity ofthe isolated DNA was evaluated by performing gel electrophoresis. Theconcentration of isolated nucleic acid was determined using NanoDrop™spectrophotometer.

To assess the neutralization of prothrombotic action of nucleic acid byUHRA-8, we performed thromboelastography experiments usingThromboelastograph Hemostasis System 5000™ (TEG) from HaemoscopeCorporation™. In this study, whole blood was mixed with nucleic acid toget a final concentration of 10 μg/mL. UHRA-8 solution was prepared inPBS (10 mM phosphate and 150 mM NaCl). 360 μL of whole blood spiked withnucleic acid was then mixed with 40 μl of UHRA (1:10 dilution, final).Then 340 μL of the sample was transferred into the TEG cup and thecoagulation analysis was initiated by re-calcifying citrated blood with20 μL of 0.2M calcium chloride solution. PBS mixed with whole blood wasused as control for the experiment.

In Vivo Studies

Efficacy of UHRAs in Animal Models of Thrombosis

Animals

Male C57BL/6 mice were obtained from Harlan Laboratories™. All animalprocedures were approved by the Institutional Animal Care and UseCommittee at the University of Illinois at Urbana-Champaign.

FeCl₃-Induced Thrombosis in Mouse Carotid Arteries.

Mice were anesthetized using an inhaled mixture of isoflurane andoxygen, and UHRA compounds diluted in sterile normal saline wereinjected retro-orbitally. The left carotid artery was exposed via amidline cervical incision and blunt dissection, and blood flow monitoredwith a Doppler vascular flow probe (Transonic™, 0.5 PSB) connected to aperivascular flow meter (Transonic™, TS420™). To induce thrombosis, twopieces of 1×2 mm filter paper (Whatman™ GB003™) saturated with freshlyprepared 5% anhydrous FeCl₃ in 0.9% saline were applied to the deep andsuperficial surfaces of the artery. After 5 minutes, the filter paperswere removed and the vessel irrigated with saline. Blood flow wasmonitored from FeCl₃ application for 30 minutes or until occlusion,defined as no detectable flow for one minute. After the experimentended, mice were euthanatized by cervical dislocation while still underanesthesia. Flow data were interpreted with LabScribe2 (iWorx Systems™).Statistical analyses were performed using GraphPad Prism 5™.

Laser-Induced Thrombosis in Mouse Cremaster Arterioles

Mice were anesthetized with an intraperitoneal injection of 125 mg/kgketamine, 12.5 mg/kg xylazine, and 0.25 mg/kg atropine sulfate.Approximately 10 minutes prior to imaging, fluorescent antibodiesagainst platelets and fibrin were injected via the jugular vein alongwith either UHRA compounds or saline. Platelets were labeled with afluorescent antibody recognizing the GPIbβ subunit of the murineGPIb-V-IX complex (rat antibody X649, conjugated to DyLight649, EmfretAnalytics™). Fibrin was labeled with mouse anti-human fibrin antibodyclone 59D8 purified from ascites fluid (a generous gift from HartmutWeiler) with Protein A/G resin (Thermo Scientific™) and labeled with anAlexa Fluor 488™ protein labeling kit according to manufacturer'sinstructions (Invitrogen™). Anesthetized mice were placed on anintravital microscopy tray and the cremaster muscle was exteriorizedthrough an incision made in the scrotum. The testis and surroundingcremaster muscle were prepared for microscopy by stretching and pinningthe tissue onto a custom-made intravital microscopy stage. The cremasterpreparation was superfused with 37° C. sterile 0.9% saline throughoutthe experiment. Brightfield and fluorescent images of arterioles wereacquired with a Zeiss Axioplan™ microscope equipped with a Lumencore4-LED light engine, a 20× water immersion lens (Zeiss W-Plan APOCHROMAT20×/1.0 NA™), and a Rolera™ em-c² EMCCD Camera (Q-Imaging™). Endothelialinjury to the vascular wall of 50-70 μm diameter arterioles thatresulted in thrombus formation was effected by the use of a 532 nmpulsed-laser system integrated with the image capture and analysissoftware (VIVO Imaging System with Ablate! Photomanipulation Module™,Intelligent Imaging Innovations™). Fluorescent and brightfield imageswere captured for 2 minutes following injury. Fluorescence images wereacquired continuously, platelet fluorescence was imaged with a Cy-5filter and 15 ms exposure, and fibrin was imaged with a fluoresceinfilter set and 10 ms exposure. Brightfield images were captured with a10 ms exposure periodically (1 image every 100 captures). Up to 6injuries were made per mouse with subsequent injuries occurring upstreamof previous ones.

Image Analysis of Fluorescent Platelet and Fibrin Accumulation

Integrated fluorescence intensity was calculated with Slidebook 5.5™(Intelligent Imaging Innovations™) as has been published previously(17). For each injury, a rectangular area was defined upstream of theinjury site including both the vessel and the surrounding tissue. Theaverage maximal values for the Cy-5 (X649, platelets) and fluorescein(59D8-Alexa Fluor 488™, fibrin) channels were used as the thresholdvalues to create masks for both platelet and fibrin accumulation. Forviewing purposes, the fluorescent pixels in FIGS. 3 and 4 (panels A-E)were binarized (value set to 1) if they exceeded the threshold. Todetermine the integrated fluorescence intensity for platelets andfibrin, only pixels above this threshold were used in data analysis (butwere not binarized). In addition, a small rectangular area was definedcompletely within the vessel upstream of the injury to serve as abackground measurement. Integrated fluorescence intensity at each timepoint was calculated as (Sum Intensity of the Mask−[BackgroundIntensity*Area of the Mask in Pixels]). Statistical analysis was done byplotting the area under the curve (total fluorescence intensity) foreach injury in a given condition and comparing the median values usingthe Mann-Whitney test. All statistical tests were done using GraphPadPrism 5.0™.

Mouse Tail Bleeding Assay

Mice were anesthetized with an inhaled mixture of isoflurane and oxygenand placed on a heated surgical tray. UHRA compound, heparin, or salinealone was injected retro-orbitally and the tail tip was immersed in a 15mL Falcon™ tube filled with PBS warmed to 37° C. for 5 minutes. After 5minutes the distal 2-4 mm of tail was transected with a new razor bladeand immediately re-immersed in the warm PBS for 10 minutes. Bleedingtime was measured with a stopwatch for the entire 10 minutes. After 10minutes, the tail was removed from the PBS and the mouse waseuthanatized by cervical dislocation. The blood samples were thenpelleted at 500×g for 10 minutes at room temperature and the pellet wasresuspended in 5 mL of Drabkin's Reagent (Sigma™) and incubated at roomtemperature for 15 minutes. The amount of hemoglobin lost was quantifiedby comparing the absorbance of the samples at 540 nm to a standard curveof bovine hemoglobin in Drabkin's reagent.

Assessment of UHRA Toxicity in Animals

Lack of UHRA 10 toxicity in vivo, wherein dose tolerance of UHRA wasexamined in mice by the administration of 100 mg/kg, 200 mg/kg ofUHRA-10 or saline control. Female Balb/C mice (6-8 weeks, 20-26 g) thatwere individually weighed and were divided into groups (n=3 for eachgroup) for each dose and injected intravenously (via tail vein) withUHRA-10 (100 mg/kg or 200 mg/kg) using a 28 G needle (injection volumewas 200 μL/20 g mouse), wherein the mice were housed in cages andmonitored for signs of acute toxicity over a period of 14 days afterinjection and body weights of individual mice were recorded prior toinjection and three times per week thereafter. On day 14, mice wereeuthanized by CO₂ asphyxiation, blood (50 μL) was collected from eachmouse on the final day and necropsy was performed on all animals. Serumsamples were analyzed for lactate dehydrogenase (LDH) activity using theIDToxTM lactate dehydrogenase enzyme assay kit (ID Labs Inc.™). Uponeuthanasia of the mice on day 14, whole liver, spleen and both thekidneys were removed from each animal. The tissues were washed in icecold saline to remove blood and immediately fixed in 10% neutralbuffered formalin and processed, embedded in paraffin, sectioned, andstained with hematoxylin and eosin (H&E). Histopathological analysis(H&E staining) on tissue sections after administration of 200 mg/kgUHRA-10 also did not show any toxicity effects such as tissue damage,cell necrosis or inflammation.

Biodistribution Studies in Mice Following i.v. and s.c. Administration

Radiolabelling of the UHRA-10 was performed by partial conversion of thehydroxyl groups to methoxide groups using tritiated methyl iodide. Twohundred milligrams of UHRA-10 was dissolved in 2 mL of anhydrous DMSOand approximately 5% of the hydroxyl groups were deprotonated usingsodium hydride. A calculated amount of tritiated methyl iodide (toluenesolution) dissolved in DMSO was added to this solution so as to achievemethylation of 1% of the hydroxyl groups. The reaction mixture wasstirred at room temperature for 15 h, 10 mL of water was added and thelabelled UHRA-10 was purified by dialysis against water using MWCO 1000dialysis membrane until the dialyzate contained low amounts ofradioactivity, this took approximately 48 h. The UHRA-10 solution wasthen filtered through 0.2 mm syringe filter and the polymer weight wasdetermined from the total volume and the polymer concentration from aknown volume of the solution after freeze-drying. The polymer solutionfor the animal study was prepared by the addition of appropriate amountof NaCl and water to achieve the desired osmolarity and the specificactivity was measured by scintillation counting.

Biodistribution studies were performed using tritiated UHRA-10. FemaleBalb/C mice (6-8 weeks, 17-23 g) were used for the entire study. Animalsfor each route of administration were divided into 9 groups (n=3) andinjected intravenously (bolus) via lateral tail vein or subcutaneouslywith UHRA-10 (concentration 2 mg/mL) at the prescribed dose of 20 mg/kg.The injected volume was 200 μL per 20 g mouse. Mice were terminated atdifferent time points (5 min, 0.5, 1, 2, 4, 24, 48, 72 h) by CO2inhalation and blood was collected by cardiac puncture. Plasma wasseparated by centrifuging the blood samples at 2500 rpm for 15 min.Aliquots of plasma were analyzed for their radioactivity byscintillation counting.

The group of mice for the 72 h time point was housed in metabolic cageand urine and feces were collected as pooled samples at different timepoints. Aliquots of urine were analyzed for radioactivity byscintillation counting. Feces were made into 10% homogenate into a knownamount of water and the radioactivity was measured by scintillationcounting.

Upon termination, major organs such as liver, spleen, kidney, heart andlung were removed from all the animals, weighed and processed forscintillation counting. Livers were made into a 30% homogenate in aknown amount of water using a polytron tissue homogenizer. Aliquots (intriplicates) of 200 mL of the homogenate were transferred toscintillation vials for counting. All other organs were dissolved in 500μL Solvable®. The vials were incubated at 50° C. overnight, then cooledprior to addition of 50 μL 200 mM EDTA, 25 μL 10 m HCl and 200 μL 30%H2O2. This mixture was incubated at room temperature for 1 h prior toaddition of 5 mL scintillation cocktail and radioactivity in the samplesmeasured by scintillation counting.

EXAMPLES Example 1 Assays for PolyP Inhibitors

In order to have clinically useful polyP inhibitors we needed compoundswith less inherent toxicity than the cationic polymers and proteinspreviously used in proof-of-principle studies of blocking polyPprocoagulant activity (8, 9). Cationic polymers still seemed like themost likely candidates for highly potent polyP inhibitors, if we couldseparate polyP-inhibiting ability from the toxicity and protein/membranebinding properties of charged polymers like polyethylenimine andcationic PAMAM dendrimers. To address this problem, we tested a seriesof UHRA compounds (originally designed as non-toxic heparin reversalagents) for their ability to inhibit polyP activity in vitro and invivo. The polymer scaffolds of this family of UHRA compounds weresynthesized by anionic ring-opening polymerization of glycidol andα-methoxy-ω-epoxy polyethylene glycol (mPEG-400), which were thenpost-functionalized to introduce positively charged groups based onbranched tertiary amines (FIG. 1A). The inclusion of a “shell” ofshort-chain PEG moieties in the UHRA compounds, together with the use oftertiary rather than primary amines, is designed to make these compoundsmuch less toxic than previously-studied polyP inhibitors containingmultiple primary amines.

UHRA compounds inhibit polyP-thrombin binding and polyP-initiated plasmaclotting in vitro. A panel of UHRA compounds were first screened forability to inhibit thrombin binding to immobilized polyP, ahigh-throughput method for identifying polyP blockers (8). UHRAcompounds 1-16, which vary in molecular weight and charge density, wereindividually screened in this assay (full data in TABLE 2). All the UHRAcompounds inhibited polyP-thrombin interactions, but with efficaciesthat were influenced by charge density (i.e., the number of R groups),since the most potent inhibition required the presence of ≧5 such Rgroups per molecule (FIG. 1B). Eleven of the UHRA compounds had IC₅₀values ≦10 nM for inhibiting thrombin binding to polyP, of which fourwere selected for further testing: UHRAs 8, 9, 10, and 14, which allinhibited thrombin binding to polyP with IC₅₀ values in the 5-8 nM range(TABLE 1). These four compounds vary in number from 7 to 24 positivelycharged R groups and vary in molecular weight from 10 to 23 kDa,allowing us to see if these two variables impact their antithromboticeffectiveness. Furthermore, these 4 compounds all have a ratio ofmolecular weight to number of polyP binding groups (kDa/R) value lessthan 1.5 (TABLE 2).

TABLE 1 In vitro inhibition of polyP activity by selected UHRA compoundsThrombin Binding Plasma Clotting Assay Size R IC₅₀ EC_(double) polyPEC_(double) RNA Compound (kDa) Groups nM ng/mL nM μg/mL μM μg/mL UHRA 823 24 5.4 ± 1.8 124 ± 41 52 ± 15 1.20 ± 0.34 0.62 ± 0.21  14 ± 4.8 UHRA9 16 16 7.6 ± 2.0 122 ± 32 80 ± 16 1.28 ± 0.26 1.9 ± 0.59 30 ± 9.4 UHRA10 10 11 7.3 ± 3.7  73 ± 37 132 ± 38  1.32 ± 0.38 2.0 ± 0.58 20 ± 5.8UHRA 14 10 7 6.6 ± 2.4  66 ± 24 92 ± 13 0.92 ± 0.13 2.2 ± 0.65 22 ± 6.5Results are: IC₅₀ for inhibiting thrombin binding to immobilized polyP(n = 5); and EC_(double) (concentration needed to double the clottingtime) in plasma clotting assays initiated with either 10 μM long-chainpolyP (EC_(double) polyP, n = 3) or 25 μg/mL polyguanylic acid(EC_(double) RNA, n = 3). Data are reported in terms of both molarityand mass/volume ± SEM.

Because the thrombin binding assay is performed in the absence of plasmaproteins that might compete for binding to polyP, we also examined theability of the four selected compounds to inhibit thrombin binding in amodified aPTT clotting assay initiated by long-chain polyP (>1000phosphates per chain) or polyguanylic acid (RNA). All four compoundsdoubled the polyP-initiated clotting times in the 50-150 nM range, andthe RNA-initiated clotting times in the 1-2 μM range (TABLE 1). Incontrast, even very high concentrations of UHRAs showed only minimalprolongation of the plasma clot time initiated by tissue factor (FIG.7). This latter finding shows that UHRAs have minimal effect on thefinal common pathway of the plasma clotting system.

TABLE 2 16 UHRA Compounds Tested in vitro Inhibition of Thrombin Bindingto PolyP MW R IC₅₀ IC₅₀ Compound (kDa) Groups kDa/R (ng/mL) (nM) UHRA 1116 33 3.52 1200 10.2 UHRA 2 48 18 2.67 166 3.5 UHRA 3 23 4 5.75 28000012000 UHRA 4 23 5 4.60 3100 136 UHRA 5 23 11 2.09 50.1 2.18 UHRA 6 23 161.44 117 5.1 UHRA 7 23 20 1.15 74 3.3 UHRA 8 23 24 0.96 123 ± 18 5.4 ±0.78 UHRA 9 16 16 1.0 122 ± 14 7.6 ± 0.90 UHRA 10 10 11 0.91  73 ± 177.3 ± 1.7  UHRA 11 9 8 1.13 38 4.2 UHRA 12 10 2 5.00 11000 1100 UHRA 1310 5 2.00 59 5.9 UHRA 14 10 7 1.42  66 ± 11 6.6 ± 1.1  UHRA 15 5 2 2.50124 25 UHRA 16 5 1 5.00 18000 3500 UHRA compounds were screened forability to inhibit thrombin binding to immobilized polyP as described inMethods. “R-groups” refers to the number of binding groups per polymer(see FIG. 1A for a general overview of UHRA structure). IC₅₀ values(given in concentrations by weight and molarity) indicate theconcentration of UHRA needed to yield 50% inhibition of thrombin bindingto polyP (n = 1-5, data reported as mean ± SEM for n > 3 and mean for n< 3). UHRA compounds 8, 9, 10, and 14 (shaded) were chosen for furtherstudy.

Example 2 Thermodynamic Parameters for Interaction of UHRA with PolyP

Both the thrombin/polyP binding assays and clotting assays wereperformed at ionic strengths lower than that of plasma. Therefore,isothermal titration calorimetry was used to determine the parametersfor binding of polyP to UHRA 8, 9, 10 and 14 at physiologic ionicstrength (FIG. 8), in order to better predict the concentrations ofthese UHRA compounds that might be needed to inhibit polyP function inblood. UHRA 8, 9, 10 and 14 bound to polyP with K_(d) values in the 0.7to 2.2 μM range (TABLE 3).

TABLE 3 Thermodynamic Parameters for Interaction of UHRA with PolyP₇₅Determined by Isothermal Titration Calorimetry K_(d) ΔG ΔH TΔS CompoundN^(a) (μM)^(a) (kcal/mol)^(b) (kcal/mol)^(a) (kcal/mol)^(b) UHRA 8 1.230.727 ± 0.01  −8.34 ± 0.01  −107 ± 0.3 −98.7 ± 0.3 UHRA 9 2.66 ± 0.0071.71 ± 0.04 −7.83 ± 0.01 −59.5 ± 0.3 −51.7 ± 0.3 UHRA 10 2.98 ± 0.0071.83 −7.79 −48.9 ± 0.2 −41.1 ± 0.2 UHRA 14 3.22 ± 0.01  2.24 ± 0.05−7.67 ± 0.01 −36.6 ± 0.3 −28.9 ± 0.3 ^(a)Obtained from isothermaltitration calorimetry experiments ^(b)Calculated from the equation ΔG =ΔH − TΔS = −RTlnK_(a)

All data were collected in PBS at pH 7.4 and 25° C. Values givenrepresent an average from two independent titrations and standarddeviations are indicated in parentheses. N: number of moles of UHRAbinding per mole of polyP₇₅; K_(d): dissociation constant; ΔG: freeenergy change; ΔH: enthalpy change; TΔS: entropy change. UHRAs exhibitedbinding affinities in the micromolar range (0.7-2.2 μM) to polyP₇₅ (apolyP preparation with median polymer lengths of approximately 75phosphate units). UHRA-8 (23 kDa with 24 binding groups) exhibited thehighest binding affinity (K_(d)=0.727 μM) among the inhibitors. At thesimilar inhibitor molecular weight, the greater the number of bindinggroups per UHRA molecule, the stronger the affinity to polyP (UHRA 10 vsUHRA 14). There was no significant difference in free energy of binding(ΔG) among the polymers; however, the enthalpy of binding (ΔH) increasedwith an increase in molecular weight as well as the number of bindinggroups on UHRAs.

Example 3 Biocompatibility of UHRA Compounds Compared to PreviouslyIdentified PolyP Inhibitors

To examine whether the unique structure of the UHRA compounds allowedthem to inhibit polyP with reduced toxic side effects, we investigatedthe interaction of UHRAs with blood components in comparison to other,previously reported polyP inhibitors such as polyethylenimine (PEI) andprotamine sulfate (8). Complement assays were performed in human serumat 37° C. by measuring the total complement consumption usingantibody-sensitized sheep erythrocyte assay. Compared to buffercontrols, complement activation was undetectable with UHRAs even at 2mg/mL (FIG. 2A). PEI and protamine, on the other hand, stronglyactivated complement. Platelet activation was studied by measuring CD62Pexpression in platelet-rich plasma. UHRAs exhibited lower levels ofplatelet activation (10-15%), compared to protamine and PEI, whichactivated platelets by about 30% and 100% respectively, when tested atthe highest dose (FIG. 2B).

Cationic PAMAM dendrimers have been identified as proof-of-principlepolyP blockers (8, 9), although this type of dendrimer is reported tohave significant toxicity in vitro and in vivo including the ability toinduce fibrin(ogen) aggregation and induce a state similar todisseminated intravascular coagulation (DIC) (10-13). Furthermore, thein vivo toxicity of amine-terminated PAMAM dendrimers increases withgeneration (reviewed by (13)), which is unfortunate because theireffectiveness in blocking polyP also increases with generation (8, 9).The ability of UHRAs 8, 9, 10 and 14 versus cationic PAMAM dendrimers(generations 1-7) were examined for their ability to induce fibrinogenaggregation (FIG. 9). Even when tested at 1.5 mg/mL, none of the UHRAcompounds showed evidence of inducing fibrinogen aggregation. On theother hand, generation 3 to 7 PAMAM dendrimers caused fibrinogenaggregation at doses from 0.2 to 1 mg/mL, confirming and expanding aprevious report of generation 7 PAMAM dendrimers inducing fibrinogenaggregation and a DIC-like state (11).

As shown in FIG. 10A, there was no change in the body weights (n=₃,reported as mean±S.D.) of mice injected with either saline (blackcircles) or UHRA 10 at doses of 100 (red squares) or 200 mg/kg (bluetriangles). Similarly, FIG. 10B shows serum lactate dehydrogenase (LDH)levels in mice injected with saline or with 100 or 200 mg/kg UHRA 10were all within the normal ranges for serum LDH in mice, which aretypically below 400 U/mL. (31, 32). There was also no evidence ofabnormalities in the histopathological analysis, further confirming thenon-toxic nature of UHRA 10 in vivo (data not shown).

Example 4 UHRA Compounds are Antithrombotic in Two Mouse Models ofArterial Thrombosis

To test the antithrombotic effectiveness of UHRA compounds in vivo, twomouse models of pathological thrombus formation were employed:laser-induced injury to cremaster arterioles and FeCl₃-induced injury tocarotid arteries. Initially, UHRAs 8, 9, 10, or 14 were administeredintravenously at 40 μg/g to mice after which cremaster arterioles wereinjured (FIG. 3). UHRAs 9 and 10 significantly reduced the accumulationof both platelets and fibrin, with UHRA 9 resulting in a 73% decrease inmedian total platelet fluorescent intensity (P=0.0006) and a 99%decrease in median fibrin total fluorescent intensity (P=0.0001)compared to saline control. UHRA 10 was similarly effective, resultingin a 63% reduction in total platelet fluorescent intensity (P=0.018) andan 88% reduction in fluorescent fibrin accumulation (P=0.0009). WhileUHRAs 8 and 14 reduced median platelet total fluorescent intensity by 41and 60% and median fibrin total fluorescent intensity by 66 and 56%respectively, these decreases were not statistically significant fromsaline controls (FIG. 3). We then varied the dose of UHRA 10 toestablish its range of effectiveness (FIG. 4). UHRA 10 significantlyreduced median total platelet fluorescence at doses of 20 and 40 μμg/g(P=0.001 and P=0.018 respectively) with a maximum inhibition of 73% atthe 20 μg/g dose. Median total fibrin fluorescence was significantlyinhibited at doses of 40 and 80 μg/g (P=0.0009 and P=0.0013respectively), with a maximum inhibition of 94% at the 80 μg/g dose.

The ability of UHRA 10 to inhibit mouse carotid arterial thrombosisinduced by topical application of FeCl₃ was also examined (FIG. 5), andit was found that a dose of 100 μg/g UHRA 10 performed as well as a doseof 200 U/kg heparin, as both treatments significantly increased themedian patency time (P=0.0004 for UHRA 10 and P=0.007 for heparin). Adose of 200 μg/g UHRA 10 was as effective as 1000 U/kg heparin incompletely blocking detectable thrombus formation for 30 minutes.

Example 5 Antithrombotic Doses of UHRA 10 Cause Less Bleeding Comparedto Heparin

In order to test if UHRA 10 causes less bleeding than heparin, a mousetail bleeding model was used to compare treatment with 50, 100, and 200μg/g doses of UHRA 10 to treatment either with saline alone or with 200or 1000 U/kg doses of heparin (FIG. 6). Mice treated with a 200 U/kgdose of heparin all had significantly longer bleeding times compared tosaline controls or mice treated with 50 or 100 μg/g doses of UHRA 10(P<0.0001, FIG. 6A). As expected, heparin-treated mice also lostsignificantly more hemoglobin due to bleeding than did saline-treatedmice (P=0.022, FIG. 6B), and although mice treated with 50 or 100 μg/gUHRA 10 lost less hemoglobin (10.8±2.4 and 7.9±1.4 mg respectively) thanheparin treated mice (15.7±4.4 mg), the differences were notstatistically significant (P=0.16 and P=0.11 respectively). Mice treatedwith the highest dose of UHRA 10 (200 μg/g) had significantly shorterbleeding times (P=0.047), but no significant difference in hemoglobinlost (P=0.55) compared to mice treated with 200 U/kg heparin (FIG. 8).

Example 6 UHRA 8 has Negligible Impact on Fibrin Clot and Whole BloodClot Structure

UHRA 8 and protamine sulfate (PS) were tested on fibrin clotarchitecture by analyzing the clots obtained in the presence of UHRA orPS using scanning electron microscopy in purified system. It wasanticipated that polycationic molecules could alter the clot structuredue to the non-specific binding (35). As shown in FIG. 12, fibrin clotsformed in the presence of UHRA did not induce any significant alterationto the fibrin clot architecture and was homogeneous in comparison to thecontrol even at a concentration as high as 500 μg/mL. In addition, noeffect of UHRA 8 was observed on the mean fiber diameter (P=0.12) (FIG.12C) and was similar to the control buffer added system. This wasconsistent with our hypothesis that UHRA 8 has minimal non-specificinteraction with proteins. On the other hand, PS even at 25 μg/mLincreased the mean fiber diameter dramatically (P<0.0001), which againcorroborate with the non-specific interaction of PS with the clottingsystem. The fiber diameter increased with increase in PS concentration.The fibrin clot with thicker fibers formed in the presence of PScorrelate to the elevated final turbidity (A₄₀₅) of clots recorded inthe fibrin polymerization assay (FIG. 11). The clot structure analysisof in presence of UHRA 8 also correlate with fibrin polymerization assay(FIG. 11); it is anticipated that fibrin clot morphology would remainsame as the control sample.

To understand the effect of UHRA 8 on whole blood clot morphology, wholeblood clots were prepared in the presence of various amounts of UHRA 8and observed by SEM. Inspection of blood clot image produced withincremental amounts of UHRA showed normal shaped erythrocytes entrappedin fibrin mesh, and abundant fibrin strands anchored to plateletaggregates similar to the control clots. Blood clots formed in thepresence of 25 and 50 μg/mL of PS, also showed normal clot signatures.However, in our experimental conditions, impaired clotting/abnormalblood clot morphology was observed at higher PS concentrations (>50μg/mL).

The activity and amount of thrombin generated are the key elements whichinfluence the formation and morphology of the blood clot (36). Previousstudies have shown that thrombin generation in human plasma and itsactivity is influenced by polycationic macromolecules such as PS (37,38). To test whether UHRA has any influence on the activity of thrombin,we assessed the activity of thrombin by measuring the ability ofthrombin (0.5 NIHU/mL) to cleave a chromogenic peptide substratefollowing incubation with UHRA. When tested at 100 μg/mL and 200 μg/mLconcentration of UHRA 8, we did not observe a change in the initial rateof chromophore release from the substrate by thrombin demonstrating thefact that UHRA 8 does not affect the activity of thrombin (data notshown). This data is corroborated with the normal whole blood clotstructure reported in the case of UHRA 8 (FIG. 13).

Previous reports confirm that impaired thrombin generation is one of thefactors responsible for the intrinsic anticoagulant property of PS. So,we evaluated the impact of UHRA 8 on TF-initiated thrombin generation byperforming a fluorogenic thrombin generation assay in pooled human PRP.Upon clotting of normal human PRP titrated with 100 and 200 μg/mLconcentration of UHRA 8, we did not observe any significant changes inparameters such as endogenous thrombin potential (ETP) and amount ofthrombin generated (data not shown). This shows that at both testedconcentrations, UHRA 8 has no impact on thrombin generation unlikeconventional polycations, and is contributing to the formation of normalwhole blood clot structure in presence of UHRA 8.

Example 7 Biodistribution and Clearance Data for UHRA-10 by Intravenousand Subcutaneous Administration

Biodistribution studies with tritiated UHRA were conducted in femaleBalb/C mice by administration via the intravenous and subcutaneousroutes. As shown in FIG. 14 UHRA 10 when administered at a dose of 20mg/kg was cleared from circulation over a period of time followingintravenous or subcutaneous injections into test mice. Similarly, asshown in FIG. 15 there was minimal UHRA 10 accumulated in liver (A),spleen (B), kidneys (C), lungs (D) and heart (E) following intravenousor subcutaneous injections into test mice. Specifically, there was verylow accumulation of UHRA-10 in liver (10% of the injected dose), inspleen (5-7% of the injected dose) and in kidneys, lungs and heart(<5%).

Similarly, as shown in TABLES 4 and 5 the clearance of 20 mg/kg oftritiated UHRA-10 from female Balb/C mice after intravenous andsubcutaneous administration is shown as the percentage of injected doseexcreted via the urine and feces. Following intravenous administration,50% injected dose of UHRA-10 is cleared from animal over 72 h. About 32%injected dose of UHRA-10 is cleared from mice following subcutaneousadministration.

TABLE 4 Clearance of UHRA 10 via Excretion into the Urine Time %Injected dose in urine (h) Intravenous Subcutaneous 2 2.90 2.29 4 4.025.47 8 7.16 2.32 24 15.93 13.02 48 2.87 2.89 72 0.77 0.69 Total 33.6526.69

TABLE 5 Clearance of UHRA 10 via Excretion into the Feces Time %Injected dose in feces (h) Intravenous Subcutaneous 0.5 0.015 0.008 10.499 0.023 2 2.523 0.199 4 3.586 1.101 8 1.840 0.830 24 1.963 0.642 486.607 0.365 72 0.015 1.586 Total 17.03 4.75

Biodistribution studies using tritium labelled UHRA (23 kDa) gave plasmacirculation of about 40 minutes with very low accumulation in vitalorgans (about 8% of the ID in the liver and 2% in spleen, kidney, heartand lung after 48 h) and was cleared mainly via kidney. All these datademonstrated the safety of the UHRAs in vivo when compared to theconventional cationic polymers.

Example 8 Reversal of Procoagulant Activities of Extracellular NucleicAcids Acid using UHRA-8

Blood spiked with 10 μg/mL of nucleic acid showed prothrombotic action.Clotting time was reduced incomparision to the control, but when UHRA-8was added to the blood containing nucleic acid, the clotting time wascomparable to that of buffer control (FIG. 16B). This shows that UHRAhas the potential to neutralize the prothrombotic action of nucleicacid. Similarly, the TEG trace also shows that clots formed in thepresence of UHRA-nucleic acid complexes are stable and has noprofibrinolytic effect (FIG. 16A).

PolyP inhibitors have recently emerged as intriguing candidates forantithrombotic therapies with a novel mode of action that differsdramatically from that of conventional antithrombotic drugs (8, 9). Wenow report the successful application of a new molecular scaffold (UHRA)for developing antithrombotic agents that target polyP. UHRAs aredendrimer-like compounds engineered to contain multiple positivelycharged, branched tertiary amines shielded by a protective layer ofshort-chain PEG groups. Binding of polycationic UHRA compounds to highlyanionic polyP is likely dominated by electrostatic interactions. Indeed,when a library of 16 UHRA compounds containing from 1 to 33 R groups wasexamined (with each R group containing four tertiary amines), we foundthat their ability to inhibit thrombin/polyP binding was influenced bythe number of R groups in the compound, with the most potent inhibitors(IC₅₀ values in the low nM range) requiring the presence of ≧5 such Rgroups. Initially the focus of our attention was on four highly potentUHRA compounds (UHRA 8, 9, 10 and 14; ranging from 7 to 24 R groups permolecule) for more detailed studies. These four compounds stronglyinhibited clotting of plasma initiated by both long-chain polyP and RNA(another procoagulant polyanion (14)), albeit with 12- to 24-fold higherpotency toward polyP than RNA.

When tested in a small-vessel arterial thrombosis model (laser-inducedinjury of cremaster arterioles), all four UHRA compounds resulted inlower median levels of accumulation of platelets and fibrin in thrombicompared to saline-treated controls, although the reductions werestatistically significant only for UHRA ₉ and 10. UHRA 14 has the sameMW as UHRA 10 but has a lower charge density (with 7 R groups in theformer and 11 in the latter), and indeed, UHRA 14 was a less effectiveantithrombotic in vivo than was UHRA 10. Interestingly, UHRA 8, whichwas consistently the best polyP inhibitor in vitro, did not perform aswell as UHRA 9 or 10 in vivo. UHRA 8 has the highest molecular weight ofthe four UHRAs that were tested in vivo, and one can speculate perhapsthe smaller UHRAs can better access the interior of forming thrombi.

Higher concentrations of UHRA 10 were needed to inhibit thrombusformation in the FeCl₃-induced carotid injury model, a findingconsistent with previous studies reporting that complete inhibition ofarterial thrombosis caused by injury with 5% FeCl₃ necessitatesantithrombotic therapy at doses high enough to induce bleeding problems(15). Laser-induced thrombosis in mouse cremaster arterioles on theother hand has been shown to be sensitive to intervention at moreclinically relevant levels of antithrombotic therapy (16, 17).

In previous toxicity studies (33), UHRAs did not show hemolysis and redblood cell aggregation even at 5 mg/mL while protamine and PEI inducedsignificant hemolysis. UHRAs compounds also did not show any effect onthrombin generation in human platelet rich plasma. UHRAs are welltolerated in mice after intravenous injection with no adverse effect upto 200 mg/kg (the maximum injected dose) in vivo and the maximumtolerated dose was not reached. In addition, mice injected with 200mg/kg UHRA had normal serum lactate dehydrogenase (LDH) levels and therewere no abnormalities observed in necropsy analysis. Histopathologyanalysis of the organs 29 days after administration also did not showany tissue damage, necrosis or inflammation, confirming the non-toxicnature of the UHRAs. Protamine, on the other hand, was only tolerated upto 20 mg/kg.

This low toxicity profile for UHRA compounds makes them more attractivefor clinical use than polyP inhibitors such as polyethylenimine,protamine, polymyxin B or PAMAM dendrimers (8, 9), many of which containmultiple primary amines. Polymyxin B has well-known toxicity in humansand is currently considered a treatment of last resort in sepsis cases(18). Protamine has demonstrated toxicity as well, includinganticoagulant effects in the absence of heparin (19, 20) and ability toprecipitate fibrinogen at high concentrations (21). Interestingly,cationic PAMAM dendrimers have also been shown to interact with andprecipitate fibrinogen in solution (11), which was confirmed in thisstudy. UHRA compounds showed no signs of these adverse interactions atconcentrations of up to 1.5 mg/mL.

The non-toxic and modular nature of UHRA compounds like the onesinvestigated in this study makes them attractive candidates for thedevelopment of clinical antithrombotic agents with a novel mode ofaction. While we cannot conclusively say that the antithrombotic natureof these compounds is entirely based on their ability to bind to polyPand inhibit its role in thrombus formation in vivo, doses of thecompound that are well-tolerated in mice were as effective as heparin ininhibiting thrombosis but with less bleeding side effects than withheparin. While heparin and heparin derivatives are some of the mostwidely used antithrombotics today, they have well-documented drawbacksthat extended even beyond the bleeding risks (5, 22).

Although the compounds that were used in this study were effective bothin vitro and in vivo in attenuating thrombus formation, compounds arecontemplated that have more or less specificity for polyP versus otheranionic polymers like extracellular nucleic acids, which have also beenimplicated in pathological thrombosis (9, 23). These could be used in avariety of antithrombotic therapeutics that could be used to moreefficiently treat the different causes of thrombosis in individualpatients. We contemplate using polyP inhibitors in sepsis anddisseminated intravascular coagulation, where not only platelet polyPbut also long-chain polyP from infectious microorganisms might playroles in pathological thrombus formation. Microbial (long-chain) polyPis orders of magnitude more effective than platelet polyP at triggeringthe contact pathway of blood clotting and can induce multipleinflammatory reactions (24-28).

Although various embodiments of the invention are disclosed herein, manyadaptations and modifications may be made within the scope of theinvention in accordance with the common general knowledge of thoseskilled in this art. Such modifications include the substitution ofknown equivalents for any aspect of the invention in order to achievethe same result in substantially the same way. Numeric ranges areinclusive of the numbers defining the range. The word “comprising” isused herein as an open ended term, substantially equivalent to thephrase “including, but not limited to”, and the word “comprises” has acorresponding meaning. As used herein, the singular forms “a”, “an” and“the” include plural referents unless the context clearly dictatesotherwise. Thus, for example, reference to “a thing” includes more thanone such thing. Citation of references herein is not an admission thatsuch references are prior art to an embodiment of the present invention.The invention includes all embodiments and variations substantially ashereinbefore described and with reference to the examples and drawings.Unless otherwise explained, all technical and scientific terms usedherein have the same meaning as commonly understood by one of ordinaryskill in the art to which a disclosed disclosure belongs.

The disclosure may be further understood by the following non-limitingexamples. Although the description herein contains many specificexamples, these should not be construed as limiting the scope of thedisclosure but as merely providing illustrations of some of theembodiments of the disclosure. For example, thus the scope of thedisclosure should be determined by the appended aspects and theirequivalents, rather than by the examples given.

Many of the molecules disclosed herein contain one or more ionizablegroups [groups from which a proton can be removed (e.g., —COOH) or added(e.g., amines) or which can be quaternized (e.g., amines)]. All possibleionic forms of such molecules and salts thereof are intended to beincluded individually in the disclosure herein. With regard to salts ofthe compounds herein, one of ordinary skill in the art can select fromamong a wide variety of available counterions those that are appropriatefor preparation of salts of this disclosure for a given application. Inspecific applications, the selection of a given anion or cation forpreparation of a salt may result in increased or decreased solubility ofthat salt. Every formulation or combination of components described orexemplified herein may be used to practice the disclosure, unlessotherwise stated.

Whenever a range is given in the specification, for example, atemperature range, a time range, or a composition or concentrationrange, all intermediate ranges and subranges, as well as all individualvalues included in the ranges given are intended to be included in thedisclosure. It will be understood that any subranges or individualvalues in a range or subrange that are included in the descriptionherein can be excluded from the aspects herein.

REFERENCES

-   -   1. Rao N N, Gomez-Garcia M R, and Kornberg A. Inorganic        Polyphosphate: Essential for Growth and Survival. Annual Review        of Biochemistry. 2009; 78(605-47.    -   2. Ruiz F A, Lea C R, Oldfield E, and Docampo R. Human platelet        dense granules contain polyphosphate and are similar to        acidocalcisomes of bacteria and unicellular eukaryotes. J Biol        Chem. 2004; 279(43)44250-7.    -   3. Morrissey J H, Choi S H, and Smith S A. Polyphosphate: an        ancient molecule that links platelets, coagulation, and        inflammation. Blood. 2012; 119(25):5972-9.    -   4. McFadyen J D, and Jackson S P. Differentiating haemostasis        from thrombosis for therapeutic benefit. Thrombosis and        haemostasis. 2013; 110(5)859-67.    -   5. Gurbuz H A, Durukan A B, Sevim H, Ergin E, Gurpinar A, and        Yorgancioglu C. Heparin toxicity in cell culture: a critical        link in translation of basic science to clinical practice. Blood        coagulation & fibrinolysis: an international journal in        haemostasis and thrombosis. 2013; 24(7):742-5.    -   6. Tessler O, Vorstenbosch J, Jones D, Lalonde S, and Zadeh T.        Heparin-induced thrombocytopenia and thrombosis as an        under-diagnosed cause of flap failure in heparin-naive patients:        A case report and systematic review of the literature.        Microsurgery. 2014; 34(2):157-63.    -   7. Dasararaju R, Singh N, and Mehta A. Heparin induced        thrombocytopenia: review. Expert review of hematology. 2013;        6(4):419-28.    -   8. Smith S A, Choi S H, Collins J N, Travers R J, Cooley B C,        and Morrissey J H. Inhibition of polyphosphate as a novel        strategy for preventing thrombosis and inflammation. Blood.        2012; 120(26):5103-10.    -   9. Jain S, Pitoc G A, Holl E K, Zhang Y, Borst L, Leong K W, Lee        J, and Sullenger B A. Nucleic acid scavengers inhibit thrombosis        without increasing bleeding. Proc Natl Acad Sci USA. 2012;        109(32):12938-43.    -   10. Jain K, Kesharwani P, Gupta U, and Jain N K. Dendrimer        toxicity: Let's meet the challenge. International journal of        pharmaceutics. 2010; 394(1⁻2):122-42.    -   11. Jones C F, Campbell R A, Brooks A E, Assemi S, Tadjiki S,        Thiagarajan G, Mulcock C, Weyrich A S, Brooks B D, Ghandehari H,        et al. Cationic PAMAM dendrimers aggressively initiate blood        clot formation. ACS nano. 2012; 6(11):9900-10.    -   12. Chauhan A S, Jain N K, and Diwan P V. Pre-clinical and        behavioural toxicity profile of PAMAM dendrimers in mice.        Proceedings of the Royal Society A: Mathematical, Physical and        Engineering Science. 2010; 466(2117):1535-50.    -   13. Sadekar S, and Ghandehari H. Transepithelial transport and        toxicity of PAMAM dendrimers: implications for oral drug        delivery. Adv Drug Deliv Rev. 2012; 64(6):571-88.    -   14. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert        C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, et        al. Extracellular RNA constitutes a natural procoagulant        cofactor in blood coagulation. Proc Natl Acad Sci USA. 2007;        104(15):6388-93.    -   15. Wang X, and Xu L. An optimized murine model of ferric        chloride-induced arterial thrombosis for thrombosis research.        Thrombosis research. 2005; 115(1-2):95-100.    -   16. Furie B, and Furie B C. In vivo thrombus formation. Journal        of thrombosis and haemostasis: JTH. 2007; 5 Suppl 1(12-7.    -   17. Jasuja R, Passam F H, Kennedy D R, Kim S H, van Hessem L,        Lin L, Bowley S R, Joshi S S, Dilks J R, Furie B, et al. Protein        disulfide isomerase inhibitors constitute a new class of        antithrombotic agents. The Journal of clinical investigation.        2012; 122(6):2104-13.    -   18. Keirstead N D, Wagoner M P, Bentley P, Blais M, Brown C,        Cheatham L, Ciaccio P, Dragan Y, Ferguson D, Fikes J, et al.        Early prediction of polymyxin-induced nephrotoxicity with        next-generation urinary kidney injury biomarkers. Toxicological        sciences: an official journal of the Society of Toxicology.        2014; 137(2):278-91.    -   19. Nielsen V G. Protamine enhances fibrinolysis by decreasing        clot strength: role of tissue factor-initiated thrombin        generation. The Annals of thoracic surgery. 2006; 81(5):1720-7.    -   20. Von Kaulla K N. Intravenous protein-free pyrogen; a powerful        fibrinolytic agent in man. Circulation. 1958; 17(2):187-98.    -   21. Stewart G J, and Niewiarowski S. Nonenzymatic polymerization        of fibrinogen by protamine sulfate. An electron microscope        study. Biochimica et biophysica acta. 1969; 194(0:462-9.    -   22. Jennewein C, Paulus P, and Zacharowski K. Linking        inflammation and coagulation: novel drug targets to treat organ        ischemia. Current opinion in anaesthesiology. 2011; 24(4)375-80.    -   23. Fuchs T A, Brill A, Duerschmied D, Schatzberg D, Monestier        M, Myers D D, Wrobleski S K, Wakefield T W, Hartwig J H, and        Wagner D D. Extracellular DNA traps promote thrombosis.        Proceedings of the National Academy of Sciences of the United        States of America. 2010; 107(36):15880-5.    -   24. Smith S A, Choi S H, Davis-Harrison R, Huyck J, Boettcher J,        Reinstra C M, and Morrissey J H. Polyphosphate exerts        differential effects on blood clotting, depending on polymer        size. Blood. 2010; 116(20):4353-9.    -   25. Semeraro F, Ammollo C T, Morrissey J H, Dale G L, Friese P,        Esmon N L, and Esmon C T. Extracellular histones promote        thrombin generation through platelet-dependent mechanisms:        involvement of platelet TLR2 and TLR₄. Blood. 2011;        118(7):1952-61.    -   26. Smith S A, and Morrissey J H. Polyphosphate enhances fibrin        clot structure. Blood. 2008; 112(7):2810-6.    -   27. Yun T H, and Morrissey J H. Polyphosphate and omptins: novel        bacterial procoagulant agents. Journal of Cellular and Molecular        Medicine. 2009; 13(10):4146-53.    -   28. Muller F, Mutch N J, Schenk W A, Smith S A, Esterl L, Spronk        H M, Schmidbauer S, Gahl W A, Morrissey J H, and Renne T.        Platelet polyphosphates are proinflammatory and procoagulant        mediators in vivo. Cell. 2009; 139(6):1143-56.    -   29. Choi S H, Collins J N, Smith S A, Davis-Harrison R L,        Rienstra C M, and Morrissey J H. Phosphoramidate end labeling of        inorganic polyphosphates: facile manipulation of polyphosphate        for investigating and modulating its biological activities.        Biochemistry. 2010; 49(45):9935-41.    -   30. Jones C F, Campbell R A, Brooks A E, Assemi S, Tadjiki S,        Thiagarajan G, Mulcock C, Weyrich A S, Brooks B D, Ghandehari H,        et al. Cationic PAMAM dendrimers aggressively initiate blood        clot formation. ACS nano. 2012; 6(11):9900-10.    -   31. Burgess E A, Sylven B. Glucose, lactate, and lactic        dehydrogenase activity in normal interstitial fluid and that of        solid mouse tumors. Cancer Res. 1962; 22:581-588.    -   32. Hayashi T, Salata K, Kingman A, Notkins A L. Regulation of        enzyme levels in the blood. Influence of environmental and        genetic factors on enzyme clearance. Am J Pathol. 1988;        132(3):503-511.    -   33. Shenoi R A, Kalathottukaren M T, Travers R J, Lai B F L,        Creagh A L, Lange D, Yu K, Weinhart M, Chew B, Du C, Brooks D E,        Carter C J, Morrissey J H, Haynes C A, and Kizhakkedathu J N.        Affinity-based design and discovery of a synthetic universal        reversal agent for clinically used parenteral heparin        anticoagulants Sci Transl Med (2014) 6(260): 260ra150.    -   34. WO2012/162789 Polymers for Reversing Heparin-based        Anticoagulation.    -   35. Zhong D, Jiao Y, Zhang Y, et al. Effects of the gene carrier        polyethyleneimines on structure and function of blood        components. Biomaterials. 2013; 34:294-305.    -   36. Wolberg A S. Thrombin generation and fibrin clot structure.        Blood reviews. 2007; 21:131-142.    -   37. Ainle F N, Preston R J S, Jenkins V P, et al. Protamine        sulphate down-regultes thrombin generation by inhibiting factor        V activation. Blood. 2009; 114: 1658-1665.    -   38. Cobel-Geard and Hassouna H I. Interaction of protamine        sulfate with thrombin. American Journal of Hematology. 1983;        14:227-233.    -   39. Travers R J, Shenoi R A, Kalathottukaren M T, Kizhakkedathu        J N, Morrissey J H. Nontoxic polyphosphate inhibitors reduce        thrombosis while sparing hemostasis. Blood. 2014 Nov. 20;        124(22):3183-90. doi: 10.1182/blood-2014-05-577932. Epub 2014        Sep. 8.

1. A method of binding a phosphate containing biological macromolecule,the method comprising adding a polymer to a phosphate containingbiological macromolecule sample, wherein the polymer comprises: a) adendritic polyglycerol core having 2-33 randomly distributed tetra-aminegroups, wherein the tetra-amines have the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4.5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system.
 2. A method of binding aphosphate containing biological macromolecule, the method comprisingadministering a polymer to a subject in need of having phosphatecontaining biological macromolecules bound, wherein the polymercomprises: a) a dendritic polyglycerol core having 5-33 randomlydistributed tetra-amine groups, wherein the tetra-amines have thefollowing structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4.5 and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system.
 3. The method of claim 2,wherein the outer shell is selected from one or more of:

wherein n is 0-100, x is 0-100 and y is 0-100; n is an integer between 1and 20, m is an integer between 1 and 20 and y is an integer between 1and 20; n is an integer between 3 and 10, m is an integer between 3 and10 and y is an integer between 3 and 10; n is an integer between 4 and9, m is an integer between 4 and 9 and y is an integer between 4 and 9;or n is an integer between 5 and 8, m is an integer between 5 and 8 andy is an integer between 5 and
 8. 4.-7. (canceled)
 8. The method of claim2, wherein the binding of the phosphate containing biologicalmacromolecule results in neutralization.
 9. The method of claim 2,wherein the phosphate containing biological macromolecule ispolyphosphate or a nucleic acid.
 10. (canceled)
 11. The method of claim9, wherein the binding to polyphosphate disrupts the interaction betweenthrombin and polyphosphate.
 12. The method of claim 2, wherein thepolyglycerol core has between 7-24 randomly distributed tetra-aminegroups or wherein the polyglycerol core has between 11-24 randomlydistributed tetra-amine groups.
 13. (canceled)
 14. The method of claim2, wherein the molecular weight of the polymer in kDa per tetra-aminegroup is between 0.9 and 4.5 or wherein the molecular weight of thepolymer in kDa per tetra-amine group does not exceed 3.6.
 15. (canceled)16. The method of claim 2, wherein the polymer has an IC₅₀ (nM) forinhibition of thrombin binding to polyphosphate is equal to or less than50 nM.
 17. The method of claim 2, wherein the polyglycerol core ishyperbranched.
 18. The method of claim 2, wherein the polyglycerol corehas a degree of branching: in the range of about 0.00 to about 1.00; inthe range of about 0.05 to about 0.95; or in the range of about 0.40 toabout 0.65. 19.-20. (canceled)
 21. The method of claim 2, wherein thepolymer is UHRA-1, UHRA-2, UHRA-5, UHRA-6, UHRA-7, UHRA-8, UHRA-9,UHRA-10, UHRA-11, UHRA-13, UHRA-14 or UHRA-15.
 22. The method of claim2, wherein the subject is administered the polymer to treat stroke,acute coronary syndrome, pulmonary embolism, atrial fibrillation, venousor arterial thromboembolism, disseminated intravascular coagulation(DIC), deep-vein thrombosis (DVT), peripheral artery disease,trauma-induced coagulopathy, extracorporeal circulation,cancer-associated thrombosis, sepsis, septic shock, SystemicInflammatory Response Syndrome (SIRS), and inflammation.
 23. The methodof claim 1, wherein the polymer is immobilized on a support.
 24. Themethod of claim 22, wherein the polymer is administered in a dose rangeof 1 mg/kg to 1000 mg/kg.
 25. The method of claim 22, wherein thepolymer is administered in a dose range of 50-100 mg/kg.
 26. The methodof claim 22, wherein the subject is non-human.
 27. The method of claim22, wherein the subject is human.
 28. The method of claim 26, whereinthe subject is a non-human mammal.
 29. The method of claim 26, whereinthe subject is a mouse, a rat, a pig, a dog, a cat, a horse, a sheep, acattle, a goat or a chicken.
 30. The method of claim 2, wherein shellpolymer is between about 10 to about 90 wt %. 31.-58. (canceled)
 59. Apolymer for inhibiting thrombin binding to polyphosphate in a subject,wherein the polymer comprises: a) a dendritic polyglycerol core having2-33 randomly distributed tetra-amine groups, wherein the tetra-amineshave the following structure

and wherein the molecular weight of the polymer in kDa per tetra-aminegroup does not exceed 4.5; and (b) an outer shell, wherein the outershell is a hydrophilic polymeric system. 60.-64. (canceled)